 
 J1I-MC -GZBF (b)  Clinical Protocol 
 
 
 A Phase [ADDRESS_1077745] 
Obesity or Are Overweight with Weight -Related Comorbidities  
 
[STUDY_ID_REMOVED]  
Approval Date: 29- Aug-2022 
 
 
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and  Company or its subsidiaries and should not be copi[INVESTIGATOR_783700]3437943 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:  A Phase [ADDRESS_1077746] Obesity or Are Overweight with Weight -Related 
Comorbidities   
Protocol Number:  J1I-MC-GZB F 
Amendment Number: b 
Compound : LY3437943   
Study Phase:  Phase 2 
Short Title:  Effect of LY3437943  versus Placebo in Participants Who Have Obesity or Are 
Overweight  
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana , [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s)  
IND: 154659  
Approval Date:  Protocol  Amendment (b) Electronically  Signed and  Approved  by [CONTACT_10937].   
Document  ID: VV-CLIN -072320  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077747] Informatio n will be provided separately .  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 3 Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY  
Document  Date  
Amendment a  21-May-2021  
Original Protocol  26-Feb-2021  
Amendment [b] 
This amendment is considered to be nonsubstantial.  
 
Overall Rationale for the Amendment:  
The overall changes and rationale for the changes made in this amendment  are described in the 
following table.  
Section # and Name  [CONTACT_9353] 1.3 Schedule of 
Activities  Pharmacokinetic (PK) sample 
row: Updated sample taken at 
Visit 17 from Predose to 
Postdose  Dosing does not occur at Visit 
17 (Week 48); therefore, time 
point is now described as 
approximately [ADDRESS_1077748] dose (Week  47). 
Pharmacokinetic Schedule of 
Events table  
Sample #10 row: Updated 
collection time point from 
“Predose (up to -8 hours)” to 
“Postdose (approximately 1 
week)”  Dosing does not occur on Week 
48. This sample collection time 
point is approximately [ADDRESS_1077749] dose.  
Pharmacokinetic Schedule of 
Events table  
Sample #11 row: Updated Week 
Relative to Randomization  from 
“End of Treatment ” to “ Safety 
follow -up” Treatment period ends at Week 
48 visit. Updated wording to 
accurately describe visit.   
Pharmacokinetic Schedule of 
Events table  
Sample #11 row: Updated 
collection time point from “[ADDRESS_1077750] dose” to “[ADDRESS_1077751] dose”  Since the last dose is on 
Week  47, the Sample #[ADDRESS_1077752] 
dose.  
Section 7.1 
Discontinuation of 
Study Intervention  Information about inadvertent 
enrollment has been removed.  Deleted as internal process will 
be followed for inadvertent 
enrollment.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 4 Section # and Name  [CONTACT_9353] 7.2.1 
Discontinuation of 
Inadvertently Enrolled 
Participants  This section has been removed.  Deleted as internal process will 
be followed for inadvertent 
enrollment.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 5 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 8 
1.1. Synopsis  ................................ ................................ ................................ ............................ 8 
1.2. Schema  ................................ ................................ ................................ ............................ 11 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 12 
2. Introduction  ................................ ................................ ................................ ................... 21 
2.1. Study Rationale  ................................ ................................ ................................ ............... 21 
2.2. Background  ................................ ................................ ................................ ..................... 21 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 22 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ............. 22 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 23 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ................................ ................... 23 
3. Objectives and Endpoints  ................................ ................................ ............................ 24 
4. Study Design  ................................ ................................ ................................ .................. 26 
4.1. Overall Design  ................................ ................................ ................................ ................ 26 
4.1.1.  Overview of Study Periods  ................................ ................................ ............................. 27 
4.1.2.  Study Procedures  ................................ ................................ ................................ ............ 31 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 32 
4.3. Justification for Dose  ................................ ................................ ................................ ......33 
4.4. End of Study Definition  ................................ ................................ ................................ ..33 
5. Study Population  ................................ ................................ ................................ ........... 34 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 34 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 35 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .41 
5.3.1.  Diet and Physical Activity Counseling  ................................ ................................ ........... 41 
5.4. Screen Failures  ................................ ................................ ................................ ................ 41 
6. Study Intervention  ................................ ................................ ................................ ........ 42 
6.1. Study Interventions Administered  ................................ ................................ .................. 42 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 43 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 43 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 44 
6.5. Concomitant Therapy  ................................ ................................ ................................ .....44 
6.5.1.  Management of Participants with Gastrointestinal Symptoms  ................................ .......45 
6.5.2.  Definition and Management of Incident Diabetes  ................................ .......................... 45 
6.6. Dose Modification  ................................ ................................ ................................ .......... 47 
6.6.1.  Temporary Interruption of Study Drug  ................................ ................................ ........... 47 
6.6.2.  Dose Reductions Indicated to Ensure Participant Safety  ................................ ................ 49 
6.7. Intervention after the End of the Study  ................................ ................................ ........... 49 
7. Discontinuation of Study Intervention and Parti cipant 
Discontinuation/Withdrawal ................................ ................................ ........................ 50 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 50 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_1077753] to Follow -Up ................................ ................................ ................................ ........... 52 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077754]  ................................ ................................ ................. 61 
8.4. Treatment of Overdose  ................................ ................................ ................................ ...68 
8.5. Pharmacokinetics  ................................ ................................ ................................ ............ 68 
8.5.1.  Bioanalysis  ................................ ................................ ................................ ...................... 68 
8.6. Pharmacodynamics  ................................ ................................ ................................ ......... 69 
8.7. Genetics  ................................ ................................ ................................ .......................... 69 
8.8. Biomarkers  ................................ ................................ ................................ ...................... 69 
8.9. Immunogenicity Assessments ................................ ................................ ......................... 70 
8.10.  Health Economics  ................................ ................................ ................................ ........... 70 
9. Statistical Considerations  ................................ ................................ ............................. 71 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....71 
9.2. Sample Size Determination  ................................ ................................ ............................ 71 
9.3. Populations for Analyses  ................................ ................................ ................................ 71 
9.4. Statistical Analyses  ................................ ................................ ................................ ......... 72 
9.4.1.  General Considerations  ................................ ................................ ................................ ...72 
9.4.2.  Treatment Group Comparability  ................................ ................................ ..................... 73 
9.4.3.  Primary Endpoint(s)  ................................ ................................ ................................ ........ 73 
9.4.4.  Secondary Endpoint(s)  ................................ ................................ ................................ ....74 
9.4.5.  Exploratory Endpoints  ................................ ................................ ................................ ....75 
9.4.6.  Other Safety Analyses ................................ ................................ ................................ .....75 
9.4.7.  Other Analyses  ................................ ................................ ................................ ................ 75 
9.4.8.  Pharmacokinetic/Pharmacodynamic Analyses  ................................ ............................... 75 
9.5. Interim Analyses  ................................ ................................ ................................ ............. 76 
9.6. Data Monitoring Committee (DMC)  ................................ ................................ .............. 76 
10. Supporting Documenta tion and Operational Considerations  ................................ ..77 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 77 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 77 
10.1.2  Informed Consent Process  ................................ ................................ .............................. 77 
10.1.3  Data Protection ................................ ................................ ................................ ................ 78 
10.1.4  Committees Structure ................................ ................................ ................................ ......78 
10.1.5  Dissemination of Clinical Study Data ................................ ................................ ............. 78 
10.1.6  Data Quality Assurance  ................................ ................................ ................................ ..79 
10.1.7  Source Documents  ................................ ................................ ................................ .......... 80 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 7 10.1.8  Study and Site Start and Closure  ................................ ................................ .................... 80 
10.1.9  Publication Policy  ................................ ................................ ................................ ........... 82 
10.1.10  Investigator Information  ................................ ................................ ................................ .82 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 83 
10.3.  Appendix 3: Laboratory Assessments for Hypersensitivity 
Events ................................ ................................ ................................ .............................. 87 
10.4.  Appendix 4: Adverse Events: Definiti ons and Procedures for 
Recording, Evaluating, Follow -Up, and Reporting  ................................ ........................ [ADDRESS_1077755] Complaints  ................................ ................................ ................... 91 
10.4.4  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 92 
10.4.5  Reporting of SAEs  ................................ ................................ ................................ .......... 93 
10.4.6  Regulatory Reporting Requirements  ................................ ................................ ............... 94 
10.5.  Appendix 5: Contraceptive Guidance and Collection of 
Pregnancy Information  ................................ ................................ ................................ ...95 
10.6.  Appendix  6: Genetics ................................ ................................ ................................ ....100 
10.7.  Appendix 7: Diet and Physical Activity Counseling  ................................ .................... 101 
10.7.1  Diet ................................ ................................ ................................ ................................ 101 
10.7.2  Physical Activity  ................................ ................................ ................................ ........... 102 
10.8.  Appendix 8: Protocol GZBF Standardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, and Vital 
Signs ................................ ................................ ................................ .............................. 104 
10.9.  Appendix 9: Liver Safety: Suggested Actions and Follow -Up 
Assessments  ................................ ................................ ................................ .................. 107 
10.10.  Appendix 10: Metabolic Mechanistic Biomarkers  ................................ ....................... 109 
10.11.  Appendix 11: Patient -Reported Outcomes  ................................ ................................ ...111 
10.12.  Appendix 12: Provisions for Changes in Study Conduct during 
Excep tional Circumstances  ................................ ................................ ........................... 113 
10.13.  Appendix 13: Abbreviations  ................................ ................................ ......................... 118 
10.14.  Appendix 14: Protocol Amendment History  ................................ ................................ 122 
11. References  ................................ ................................ ................................ .................... 124 
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 8 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:  A Phase [ADDRESS_1077756]  Obesity or Are Overweight with Weight -Related 
Comorbidities   
Short Title:  Effect of LY3437943 versus Placebo in Participants Who Have Obesity or Are 
Overweight  
Rationale : 
Obesity is a chronic disease and its increasing prevalence is a public health concern associated 
with rising incidence of type 2 diabetes (T2D), increased risk for premature death, and increased 
risk for some cancer s (AMA  2013;  Council on Science and Publi c Health 2013 ; Lauby -Secretan 
et al. 2016 ). There remains an unmet need in the pharmacologic treatment of obesity for drugs 
that are safe,  efficacious, and well tolerated.  
LY3437943 is a novel synthetic peptide , which shows potent agonist action at glucose -dependent 
insulinotropic polypeptide (GIP), glucagon -like peptide -1 (GLP -1), and glucagon (Gcg) 
receptors ( GIPR , GLP -1R, and GcgR) . It includes a linear  peptide component of 39 amino acid 
residues conjugated  to a C20 fatty acid moiety . In nonclinical pharmacology models, 
LY3437943 demonstrated  greater  weight loss in diet -induced obese (DIO) mice  compared with 
an existing GLP -[ADDRESS_1077757] (GLP -1RA) . The body  weight reduction in DIO  mice  was 
primarily due to loss of fat mass and was associated with lowered total plasma cholesterol and 
reduced liver fat content . In addition, LY3437943 demonstrated a greater effect  on glucose -
dependent insulin secretion  compared with an existing GLP -1RA, as demonstrated by 
[CONTACT_783709]. Data from the Phase 1 program  in patients with 
T2D demonstrated that LY3437943 has the potential to induce  clinically meaningful weight loss  
(that is , 5%-10% or more)  with a safety pro file consistent with other GLP -1 and GIP/GLP -1RAs.  
Study J1I-MC-GZBF  (Study GZBF ) will investigate the safety and efficacy  of 48 weeks of 
treatment with LY3437943 , administered subcutaneously once  weekly (QW) , in participants  who 
have obesity (BMI ≥ 30 kg/m2) or are overweight (BMI ≥ 27 kg/m2 and < 30 kg/m2) with 
weight -related comorbidities  but without T2D. The primary objective will be the effect on 
percent change in body weight  at [ADDRESS_1077758] obesity or are overweight with weight -related comorbidities . 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 10 Intervention Groups  and Duration : 
Study participants will be randomly assigned  in a 2:1:1:1:1:2:2 ratio (LY3437943 1 mg QW, 
LY3437943 4 mg QW  [with starting dose at 2 mg ], LY3437943 4 mg QW  [with starting dose at 
4 mg ], LY3437943 8 mg QW  [with starting dose at 2 mg ], LY3437943 8 mg QW  [with starting 
dose at 4 mg ], LY3437943 12 mg QW  [with starting dose at 2 mg ], placebo  QW) and stratified 
by [CONTACT_783710]  ≥ 36 kg/m2.  
All participants will receive diet and physical activity counseling using a standardized approach  
throughout the study . 
Study  GZBF  will consist of 3 periods: a 6-week screening period , a 48-week double -blind , 
placebo -controlled treatment period (consisting of a n up to  12-week dose-escalation period  and a 
36-week maintenance  period ), and a 4-week safety  follow -up period . 
Data Monitoring Committee:  No
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 11 1.2. Schema  
 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 19 Abbreviations:  ABPM  = ambulatory blood pressure monitoring;  ADA  = anti -drug antibody;  BP = blood pressure; CKD -EPI = Chronic Kidney Disease -
Epi[INVESTIGATOR_623];  ECG  = electrocardiogram; ED = early discontinuation of treatment ; eGFR  = estimated glomerular filtration rate ; HbA1c  = hemoglobin A1c ; 
IWRS= Interactive Web Response Systems; MRI = magnetic resonance imaging ; NAFLD = non-alcoholic fatty liver disease ; PK = pharmacokinetics ; PR = 
pulse rate; SF-36v2 acute form  = Short Form -36 Version 2 Health Survey acute form ; TXP = treatment period . 
 
General Note s: 
 Telephone visits are shaded . 
 Visit [ADDRESS_1077759] be completed before processing the randomization in the interactive web -response system (IWRS ). 
 The interval between Visit 1 and Visit 4 can be accomplished in less than 6 weeks and will not be considered as a protocol deviation.  If the ABPM 
needs to be repeated at Visit 3 (per criteria specified in Section [IP_ADDRESS] ), then the screening period may exceed 6 weeks and this will not be considered a 
protoc ol deviation.  
 Participants who do not qualify for the MRI  should move from Visit 1 to Visit 3.    
 The visit date is determined in relation to the date of Visit 4 (randomization).  
 Participants who are unable or unwilling to continue the study  drug for any reason will perform an ED visit. If the participant is discontinuing during an 
unscheduled visit or a scheduled visit, that visit should be performed as an ED visit.  
 Visit 99 is only applicable to participants who discontinue the double -blind study  treatment prematurely and decline to complete the remaining 
scheduled study visits. If the participant is unwilling to complete all the study visits, then the participant should be encouraged to come back for a Visit 
99, 48 weeks ± [ADDRESS_1077760] that the participant has refused to attend.  
 Visit 801 (safety follow -up visit) should be performed [ADDRESS_1077761] visit during the study treatment period  or Visit 99 .  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 20  Pharmacokinetic Schedule of Events  
Sample #  Week Relative to Rand omization  Collection Timepoint Relative to LY3437943 Weekly Dose  
1 0 Predose (up to -8 hours)* 
2 1 1 to 24 hours postdose  
3 4 Predose (up to -8 hours)* 
4 8 24 to 72 hours postdose  
5 12 Predose (up to -8 hours)* 
6 16 72 to 168 hours postdose  
7 20 Any time  during this week  
8 24 Predose (up to -8 hours)* 
9 36 Any time during this week  
10 48 Postdose ( approximately 1 week )* 
[ADDRESS_1077762] dose  
12 Early discontinuation  Any time  
* Immunogenicity (ADA) samples collected with PK at these visits . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 22 Summary of clinical studies  
Study J1I -MC-GZBA (GZBA)  was a  first-in-human , single -ascending dose study investigating  
the safety, tolerability, and pharmacokinetic/pharmacodynamic ( PK/PD) of LY3437943 
administered as a SC injection in  [ADDRESS_1077763] common treatment -emergent adverse events  (TEAEs ) were gastrointestinal ( GI) 
events, including vomiting (with higher doses), abdominal distention, and nausea, which were 
dose dependent, mostly mild in severity,  occurred within 4 days of dosing, and resolved within a 
week of onset . Dose -dependent in creases in heart rate  (HR)  and decreases in systolic blood 
pressure (BP) were observed, which returned to near baseline  by [CONTACT_2006] 29 .  
Across dose levels, the m aximum  observed  drug concentration (C max) occur red between ~1 and 
3 days postdose, while t he mean terminal half -life was  ~5 to 7 days, thus supporting a QW 
dosing regimen .  
Study J1I -MC-GZB B (GZB B) is a Phase 1, randomized, investigator - and participant -blind 
study t hat assess ed the safety, tolerability, and PK/PD effects of multiple doses of LY3437943 
when administered QW in participants  with T2D . Trulicity® (dulaglutide)  1.5 mg  was used as a n 
active comp arator . Participant s in Cohorts 1 to 3 received fixed doses of LY3437943 (0.5, 1.5 , 
and 3 mg QW ) or placebo  for 12 weeks . Participants in Cohort s 4 and 5 received placebo or 
LY3437943 titrated from a starting dose of 3 mg QW to maximum doses of 6 mg QW (Cohort 4) 
and 12 mg  QW (Cohort 5)  over the 12-week  treatment period . 
Based on preliminary data  from this ongoing study , 72 participants received study treatment, and 
43 completed the study  to date.  Gastrointestinal adverse events (AEs) (nausea, abdominal 
distention, and diarrhea ) and decreased appetite were the most frequently reported events, mostly 
mild in severity and dose dependent . A dose dependent increase in HR was noted.  The HR 
effects were consistent with those of the GLP -1 or GIP/GLP -1RA class , as was seen in Phase 1 
clinical development. There were no reports of severe hypoglycemia or AEs related to the site of 
injection . Overall, data from early phase clinical trials support further devel opment of 
LY3437943 in Phase 2 studies .  
2.3. Benefit/Risk Assessment   
This section summarizes the key observations from the completed or ongoing Phase 1 trials with 
LY3437943.  More detailed information about the known and expected benefits and risks and 
reasonably expected  AEs of LY3437943  may be found in the Investigator’s Brochure  (IB). 
Information on AEs expected to be related to the investigational product may be found in Se ction  
6.2 (Development al Core Safety Information)  of the IB. Information on serious adverse event s 
(SAEs ) that are expected in the study population independent of drug exposure will be assessed 
by [CONTACT_240209], periodically during the course of  the study, and may be found in 
Section  7 (Reference Safety Information for Assessment of Expectedness of Serious Adverse 
Reactions ) of the IB . 
2.3.1.  Risk Assessment  
The m ost common AEs observed in the LY3437943 clinical trials in health y participants  and 
participant s with T2D have been GI effects. There are safety topi[INVESTIGATOR_783701] -1 and GIP/GLP -1RA  clinical programs , including  pancreatic safety, 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 23 cardiovascular events, hypoglyce mia, hypersensitivity reactions , and thyroid C -cell effects ; refer 
to Section 8.3.[ADDRESS_1077764] 
obesity or are overweight with weight -related comorbidities , in addition to safety and PK/PD 
assessments.   
2.3.3.  Overall Benefit: Risk Conclusion  
The data from Phase 1 studies indicate that the safety profile of LY3437943  is consistent with 
the safety profile of other GLP -1 and GIP/GLP -1RAs . No additional risks are anticipated.  
Considering  the measures to minimize risk to participants includ ed in the study protocol , 
potential risks identified in association wit h LY3437943  are considered acceptable in this study . 
No benefits of LY3437943  can be assumed because LY3437943 is in the early phase of clinical 
development.  All participants in this study will receive diet and physical activity counseling .  
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 25 Objectives  Estimands/ Endpoints  
 Lipid parameters   Mean change in  fasting  
o total cholesterol  
o HDL  cholesterol  
o LDL  cholesterol  
o VLDL  cholesterol  
o triglycerides  
 Glycemic control   Mean change in  
o fasting glucose  
o HbA1c  
 Proportion of participants with incident T2D  
 
 Mechanistic biomarkers   Mean c hange  in mechanistic biomarkers (see 
detailed list of parameters in Section  10.10 ) 
 Patient -reported outcomes   Proportion of participants with change in 
PGIS -Physical Function  
 Mean change in  
o SF-36v2 acute form domain score s  
o Eating Inventory domain scores  
 To assess the PK of LY3437943 and potential 
participant factors that may influence its PK   LY3437943 plasma concentrations  
 To assess the relationship between 
LY3437943 dose and/or exposure and key 
efficacy and safety measures and potential 
participant factors that may influence these 
relationships   Dose –response and concentration –response 
analyses for key efficacy and safety 
parameters  
Abbreviations: ABPM  = ambulatory blood pressure modeling;  BMI = body mass index; HbA 1c = hemoglobin A1c; 
HDL  = high-density lipoprotein; LDL  = low-density lipoprotein; PGIS  = Patient Global Impression of Status;  
SF-36v2  acute form  = Short Form -36 Version 2 Health Survey acute form; VLDL  = very low -density lipoprotein . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077765] obesity  (BMI ≥ 30 kg/m2) or are overweight (BMI ≥ 27 kg/m2 and < 30 
kg/m2) with weight -related comorbidities  but without T2D. The primary objective will be the 
effect of LY3437943  on percent change in body weight  at [ADDRESS_1077766]  obesity  or are  overweight with 
weight -related comorbidities . 
All participants will receive diet and physical activity counseling using a standardized approach 
throughout the study  (Section 5.3.1 ). 
Participants with high probability of non-alcoholic fatty liver disease  (NAFLD)  and for liver fat 
≥10% as determined by [CONTACT_783711] (see Section [IP_ADDRESS] ) will undergo liver 
fat assessment by [CONTACT_9252] -derived proton density fat fraction  (MRI -PDFF). 
Participants with baseline liver fat  equal to or higher than 10 % as assessed by  [CONTACT_9268] -PDFF  will be 
invited to participate in an addendum study in which the effect of LY3437943  on liver fat and 
serum biomarkers of nona lcoholic steatohepatitis will be evaluated . Approximately 100 -125 
participants will be included in this addendum study.  
Four maintenance doses of LY3437943 will be evaluated in the trial : 1, 4, 8 , and 12 mg. Dose  
escalation to improve GI tolerability will occur in certain treatment groups up to Week 12 by 
[CONTACT_597983] (or placebo) . For maintenance doses equal to 
or greater than 4 mg, the initial dose will be 2 or 4 mg followed by [CONTACT_783712]. 
For 2 of the maintenance dose arms  (4 and 8 mg), participants will be randomly assigned  into 2 
subgroups , designated by (a) an d (b), with different dose escalation schemes. Th is is described in 
detail in Section 4.1.1 . 
Study participants will be randomly assigned  in a 2:1:1:1:1:2:2  ratio ( LY3437943 1 mg QW, 
LY3437943 4 mg QW  [a], LY3437943 4 mg QW  [b], LY3437943 8 mg QW  [a], LY3437943 8 
mg QW [b], LY3437943 12 mg QW, placebo QW ) and stratified by [CONTACT_783710]  ≥ 36 kg/m2. 
An upper limit of 60% enrollment of women will be used to ensure a sufficiently large sample of 
men.  
Study  GZBF  will consist of 3 periods: a 6-week screening period , a 48-week double -blind, 
placebo -controlled treatment period (consisting of an up to 12 -week dose -escalation period and a 
36-week maintenance  period ), and a 4 -week safety follow -up period .  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 27 4.1.1.  Overview of Study Periods  
[IP_ADDRESS].  Main Study Period  
Screenin g Period  
Visit [ADDRESS_1077767] sign 
the informed consent form (ICF) before the study procedures are performed, as outlined in the 
SoA, Section 1.3. Since some screening procedures need to be completed in the fasting state  
(approximately 8 hours without eating, drinking [except water ], or performing any significant 
physical activity ), Visit 1 may be conducted over more than 1 day to ensure necessary conditions 
are met.  Participants who meet  all applicable inclusion criteria and none of the applicable 
exclusion criteri a (Sections 5.1 and 5.2) at Visit  1 will continue in the study . Participants who do 
not qualify for the magnetic resonance imaging (MRI ) should move directly from Visit 1 to Visit 
3. 
Visit 2  
Participants  identified w ith a high probability for liver fat ≥10% as determined by [CONTACT_783713] [ADDRESS_1077768].  
Visit 3  
Eligible  participants (individuals who meet all applicable inclusion criteria and none of the 
applicable exclusion criteria ) will receive education about ambulatory blood pressure monitoring 
(ABPM ) and will be trained in its use at Visit 3. Ambulatory monitoring of HR and BP should  be 
performed prior to Visit 4. Details on ABPM are described in Section 4.1.2 .3. Diet and physical 
activity counseling will begin at Visit 3 so that participants will be familiar with the program 
prior to randomization  (Section 5.3.1 ). This counseling will be provided at all subsequent visits 
until Week 44 ( Visit 16 ). 
Treatment Period  
Randomization  (Visit 4)  
At Visit 4, ABPM results will be analyzed to ensure that at least 70% of the readings are valid  as 
described in Section [IP_ADDRESS] . Eligible p articipants with acceptable  ABPM data  (as described 
Section [IP_ADDRESS] ) will perform all required procedures prior to randomization  and prior to taking 
the first dose of study drug. If the ABPM results are not acceptable, randomization (Visit 4) 
should  be rescheduled , and ABPM needs to be performed again within 1 week  and prior to  the 
rescheduled  Visit 4. At Visit 4, s tudy participants are required to report after approximately 8 
hours without eating, drinking (except water) , or performing any significant physical activity.  
When collected, p atient -reported outcomes questionnaires should be administered as early as 
possible in the visit , prior to randomization . Preferred administration order is  
1. Patient Global Impression of Status  for Physical Activity   
2. SF-36v2 acute form , and  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 28 3. Eating Inventory.  
The mental health questionnaires  (PHQ -9, C-SSRS, and Self-Harm Form ) should be completed  
after the assessment for AEs.  
Following randomization, study site personnel will demonstrate  study drug preparation and 
injection  technique using a vial and  syring e and observe the study participant inject the first dose 
of LY3437943  or placebo. The date , time, and location  of the first dose of study drug will be 
recorded on the electronic case re port form  (eCRF) . Beginning at randomization, all participants 
will receive study drug according to the randomized treatment arm for the duration of the 
48-week treatment period .  
Visit [ADDRESS_1077769]  5-9 days after Visit 4. S tudy participants are required to report after 
approximately 8 hours without eating, drinking (except water) , or performing any significant 
physical activity.  The mental health questionnaires (PHQ -9, C-SSRS, and Self -Harm Form) 
should be completed after the ass essment for AEs  during visits as indicated in the S oA, Section 
1.3. Study site personnel will review the study drug  preparation and injection technique using a 
vial and syringe and then observe the study participant inject the second dose of LY3437943  or 
placebo.  The date , time, and location  of the second  dose of study drug will be recorded on the 
eCRF . 
Dose -Escalation  Period  (Visits 6-8) 
Dose  escalation will occur in certain treatment groups up to Week 12 of treatment. On Visit 6 
through Visit 8, study participants are required to report after approximately 8 hours without 
eating, drinking (except water) , or performing any significant physical activity.  The mental 
health questionnaires (PHQ -9, C-SSRS, and Self-Harm Form ) should be completed after the 
assessment for AEs  during visits  as indicated in the S oA, Section 1.3. For maintenance doses 
equal to or greater than 4 mg, the initial dose will be 2 or 4 mg followed by [CONTACT_783714]. The dose will be increased at 4 -week increments until 
the maintenance dose is achieved ( Section 6.1 for details) , as follows:  
 Maintenance dose of 1 mg: no dose escalation  
 Maintenance dose of 4 mg will be randomized 1:1 into 2 subgroups :  
o Subgroup (a): 2 mg (Visit 4)   4 mg (Visit 6)  
o Subgroup  (b): 4 mg (no dose escalation)  
 Maintenance dose of 8 mg  will be randomized 1:1 into 2 sub groups :  
o Subgroup (a): 2 mg (Visit 4)   4 mg (Visit 6)   8 mg (Visit 7)  
o Subgroup (b): 4 mg (Visit 4)   8 mg (Visit 6)  
 Maintenance dose of 12 mg:  
o 2 mg (Visit 4)  4 mg (Visit 6)   8 mg (Visit 7)  12 mg  (Visit 8) . 
Maintenance dose will be continued for the  remainder of the study. Study site personnel will 
review the study drug  preparation and injection technique using a vial and syringe at each visit. 
Refer to Section 6.5.1  and 6.6 for guidance on management of participants who experience GI 
symptoms . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 29 Main tenance  Period  (Visits 9 -17) 
During the maintenance  period, visits will occur monthly through 48 weeks.  Telephone visits 
will occur at Weeks 28,  32, 40, and 44. For office visits , study participants are required to report 
after approximately 8 hours without eating, drinking (except water) , or performing any 
significant physical activity.  Office and telephone visit procedures should be conducted 
according to the SoA (Section  1.3). At Visit 11 and Visit 17, when collected, patient -reported 
outcomes questionnaires should be administered as early as possible in the visit . Preferred 
administration order is  
1. Patient Global Impression of Status for Physical Activity  
2. SF-36v2 acute form , and 
3. Eating Inventory.  
The mental  health questionnai res (PHQ -9, C-SSRS, and Self-Harm Form ) should be completed 
after the assessment for AEs during visits as indicated in the S oA, Section 1.3.  
ABPM will be repeated at Week 24 (Visit 11) and Week 36 (Visit 14) as described in Section 
[IP_ADDRESS] . Study drug and injection supplies will be returned per the SoA ( Section  1.3) and 
according to local requirements. New supplies will be dispensed as needed.  Study site personnel 
will review the study drug  preparation and  injection technique using a vial and syringe at each 
office visit. Participants should be instructed to contact [CONTACT_783715]. Additional 
unscheduled visits may be scheduled if the participant needs  additional support  for the study 
drug injection technique.  
Participants should also be advised about the appropriate course of action if study drug is not 
taken at the required time ( for details on late/missing doses , see Section s 6.1 and 6.6). Study 
participants will be permitted to use concomitant medications that they require during the study, 
except cer tain excluded medications (see Section 6.5) that may interfere with the assessment of 
efficacy and safety characteristics of the study treatments.  
Early Discontinuation of Treatment  Visit  
Participants unable or unwilling to continue the study treatment  for any reason will perfo rm an 
early discontinuation of treatment (ED)  visit. If the participant is discontinuing during an 
unscheduled visit or a sch eduled visit, that visit should be performed as an ED visit. A study 
participant who discontinues study drug permanently should be encouraged to continue in the 
study and to complete all study visits, including Vis it 801 (See Participant Disposition and 
Timing of Safety Follow -Up figure below).  Procedures should be completed according to the 
SoA (Section 1.3). When collected, patient -reported outcomes  questionnaires  should be 
administered as early as possible  in the visit. Preferred administration order is  
1. Patient Global Impression of Status for Physical Activity  
2. SF-36v2 acute form , and 
3. Eating Inventory.  
Mental health questionnaires (PHQ -9, C-SSRS, and Self-Harm Form ) should be completed after 
the assessment for AEs.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 30 Visit 99  
A study participant who discontinues study drug permanently should be encouraged to continue 
in the study and to complete all study visits. If the participant is unwilling  to complete all the 
study visits, then the participant should be encouraged to come back  for a study visit 48  weeks (± 
7 days ) after randomization , which is designated as Visit 99 in the SoA (See Participant 
Disposition and Timing of Safety Follow -Up figure below). This visit is critical to ensure 
complete data collection for the Week [ADDRESS_1077770] . 
Safety Follow -Up Period  (Visit 801 ) 
Participants who complete the study treatment period should perfo rm a Visit 801 (safety follow -
up visit) [ADDRESS_1077771] treatment visit (Visit 17). Participants who complete a Visit 99 
should perform a Visit 801 four weeks after Visit 99. Participants who stop study drug early, and 
decline to complete visits to 48 weeks (including Visit 99), should perform a Visit 801 (safety 
follow -up visit) [ADDRESS_1077772] visit of the treatment period and then discontinue the study 
(See Participant Disposition and Timing of Safety Follow -Up figure below). During the safety 
follow -up period, participants will not receive study dru g.  
Mental  health questionnaires (PHQ -9, C-SSRS, and Self-Harm Form ) should be completed after 
the assessment for AEs.  
Participants are also required to return any r emaining study diaries to the study site at the end of 
this period.  
Participant Disposition and Timing of Safety Follow -Up 
 
Abbreviations: ED  = early discontinuation of treatment ; Wks  = weeks 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 32 Ambulatory BP measurements  
 should be collected on a typi[INVESTIGATOR_724650], not on a non -working day  
 will be recorded every 30 minutes during daytime hours (0700 to 2200 hours) , and  
 will be recorded eve ry 60 minutes during nighttime hours (2200 to 0700  hours). 
A 24 -hour session of ambulatory monitoring produces technically acceptable measurements if 
≥70% of the readings are valid . Between Visit 3 and Visit 4 (Week 0)  and within 7 days 
following Visit 11 (Week 24) and Visit 1 4 (Week 36), participants  will undergo a [ADDRESS_1077773] be 
transmitted to the Core Laboratory and reviewed for validity of the readings  before the 
particip ant leaves the site. If a technically satisfactory result is  not achieved  (less than 70% of 
readings are valid) , the investigator should review the device settings and placement and the 
participant’s activity track to correct any user error or device malfu nctions. Another 24 -hour 
ambulatory monitoring session should be conducted prior to Visit 4 (Randomization) or within 
14 days following  Visit 11  and Visit 14, respectively . If the second session also provides 
technically unsatisfactory results, data will b e considered missing  and the participant may 
continue in the study .  
4.2. Scientific Rationale for Study Design  
Data from the Phase 1 program in patients with T2D demonstrated that LY3437943 has the 
potential to induce clinically meaningful weight loss (that is, 5%-10% or more) with a safety 
profile consistent with other GLP -1 and GIP/GLP -1RAs.  
The placebo arm is included to determine whether any efficacy or safety effects of LY3437943 
are different in magnitude from no treatment (that is, placebo).  Althou gh it will not be feasible to 
blind t he participant and the investigator to the injection volume of study drug, they will not 
know whether the participant is receiving LY3437943 or placebo. To preserve the blind, 
participants randomized to placebo wil l be ran domly assigned to follow the injection dose 
schedule for 1 of the LY3437943 treatment arms. 
Consistent with current guidelines for weight management , all participants will receive diet and 
physical activity counseling throughout the study , which will  be based on guidelines published 
by [CONTACT_941] U.S. Department of Agriculture and U.S. Department of Health and Human Services  
(HHS 2018; USDA and HHS 2020 ).  
The primary efficacy measure, mean percent change in body weight , is an accepted Phase 2 
endpoint for investigational drugs being developed for weight man agement  (FDA 2007) . In 
addition, the protocol includes other parameters relevant to assessment of the effects of 
LY3437943 on  safety , BP, HR, lipi[INVESTIGATOR_805], glycemic control, mechanism of action, PK parameters , 
and patient -reported out comes.  
The primary objective will be  evaluated  at 24 weeks because this period is considered adequate 
for evaluation of weight loss efficacy in a Phase 2 trial  and sufficient to assess the dose–
exposure –response of LY3437943 effic acy for selection of doses to be included in Phase 3 
testing. The planned 48 -week treatment period should be sufficient  to capture the maximal or 
near-maximal weight loss effects  of LY3437943 . The putative mechanism of action of 
LY3437943 suggests that tre atment with LY3437943 will result in continued weight loss over 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077774] benefit –risk characterizations in treatment of 
participant s who have obesity or are overweight . 
LY3437943 was well tolerated up to a 3 mg dose in the single ascending dose study ( Study 
GZBA) and up to a 12 mg dose with gradual dose escalation in the multiple ascending dose 
study (St udy GZBB) . Therefore, the highest dose in this study will be [ADDRESS_1077775] of changes to concomitant medications, 
participants  will be permitted to use concomitant medications that do not interfere with the 
assessment of efficacy or safety characteristics of the study treatments.  
The sample size is  determined based on data from Study GZBB that provided preliminary P D 
data for LY3437943 in participants with T2D  over a 12 -week treatment period , and on data from 
the semaglutide  Phase 2 obesity study (O’Neil et al. 2018) . 
4.3. Justification for Dose  
LY3437943  doses of 1, 4, 8, and 12 mg, administered  subcutaneously QW, were selected based 
on the following  
 Safety and tolerability of LY3 437943  in healthy participants  and partic ipants  with T2D  in 
the Phase 1 stud ies GZBA (0.1 to 6 mg  dose range ) and GZBB  (0.5 to 12 mg dose range ). 
 PK/PD modeling of preliminary data from Study GZBB . 
 Acceptable  margin of safety for the [ADDRESS_1077776] level in rats and monkeys in the  6-month toxicology studies.  
 A maintenance dosage of  1 mg is predicted to achieve LY3 4379 43 concentration levels 
that will demonstrate greater body weight  loss compared with placebo  and is being 
investigated  in this study to enable full characterization of exposure –response  
relationship s.  
 Maintenance d osages  of 4, 8, and [ADDRESS_1077777] on tolerability  and safety findings . 
 The selected dose levels and dose range will  support a robust dose –exposure –response  
analysis of multiple safety and efficacy measures to support selection of dose(s) o f 
LY3437943  with optimal benefit/risk ratio for further clinical development . 
4.4. End of Study  Definition  
A participant is considered to have completed the study if he  or she has completed all required 
phases of the study including  the last visit  or the last scheduled procedure shown in the SoA . 
The end of the study is defined as the date of the last visit of the last participant in the study or 
last scheduled procedure shown in the S oA for the last participant in the trial globally.  
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 34 5. Study Population  
Prospective approv al of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted . 
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all the following criteria apply:  
Age 
1. Participant must b e [ADDRESS_1077778] a BMI  of 
 ≥30 kg/m2 and ≤50 kg/m2 
 ≥27 kg/m2 and <30 kg/m2 with at least 1 of the following weight -related 
comorbidities  
o hypertension : on BP-lowering medication or having systolic  BP 
≥130  mmHg or diastolic BP ≥80 mmHg  at screening  
o dyslipi[INVESTIGATOR_035] : on lipid -lowering medication or having low -density 
lipoprotein ( LDL ) ≥160 mg/dL (4.1 mmol/L) or triglycerides ≥150 
mg/dL (1.7 mmol/L) , or high-density lipoprotein ( HDL ) <40 
mg/dL (1.0 mmol/L) for men or HDL <50 mg/dL (1.3 mmol/L)  for 
women at screening  
o cardiovascular  disease : (for example, ischemic cardiovascular 
disease,  [LOCATION_001] Heart Associatio n [NYHA ] Functional 
Classification Class I -II heart failure)  
3. In the investigator’s opi[INVESTIGATOR_1649], are well motivated , capable, and willing to  
 learn how to self -inject study drug, as required for this protocol (visually impaired 
persons who are not able to perform the injections must have the assistance of a 
sighted individual trained to inject the study drug; persons with physical 
limitations who are not able to perform the injec tions must have the assistance of 
an individual trained to inject the study drug)  
 inject study drug (or receive an injection from a trained individual if visually 
impaired or with physical limitations) , and  
 follow study procedures for the duration of the study, including, but not limited 
to, follow lifestyle advice (for example, dietary changes  and physical activity  
plan), maintain a study drug administration log , and complete required 
questionnaires . 
In addition,  a subgroup  of approximately 100-[ADDRESS_1077779] liver fat content ≥10% by [CONTACT_9268] -PDFF  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 35 Sex 
5.  Male and/or female  
Contraceptive use by [CONTACT_783716] . 
Males , women of childbearing  potential and women not of childbearing potenti al 
(for definitions , see Section 10.5 [Appendix 5]) can participate in this study  
considering the following : 
 males agree  to refrain from sperm donation and  to use contraceptive methods as 
described in  Section 10.5 (Appendix 5) throughout the study and for [ADDRESS_1077780] injection.  
 women of childbearing potential  must have  negative pregnancy test s at Vis it 1 and 
Visit 4 a s indicated in the SoA and agree to use contraceptive methods as 
described in  Section  10.5 (Appendix 5) throughout the study and for [ADDRESS_1077781] injection.  Female 
participants should not be breastfeeding.  
Note:  Hormon e replacement  therapy in postmenopausal women and contraceptives 
containing an estrogen and a progestin (oral or transdermal system) in premenopausal 
women are allowed but women must be on stable therapy for 3 months prior to 
screening.  
Informed  Consent  
6. Capable of giving signed informed consent as describ ed in Section 10.1 (Appendix 
1), which includes compliance with the requirements and restrictions listed in the ICF 
and in this protocol . 
5.2. Exclusion C riteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
Diabetes  Related  
7. Have history of diabetes mellitus including T1D or T2D, history of keto acidosis , or 
hyperosmolar state/coma  
8. Have  at least 1 laboratory  value suggestive  of diabetes during screening , including 1 
or more of HbA1c ≥6.5% (48 mmol/mol), fasting serum glucose ≥126 mg/dL 
(7.0 mmol/L), or random glucose ≥200 mg/dL (11.1 mmol/L)  
Obesity  Related  
9. Have  a self -reported change (increase or decrease)  in body weight >[ADDRESS_1077782]  a prior or planned surgical treatment for obesity (excluding liposuction or 
abdominoplasty, if performed >1 year prior to screening)  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077783] endoscopic and/or device -based therapy for obesity or have had 
device removal within the last 6 months prior to screening  including but not limited to  
 mucosal ablation  
 gastric artery embolization  
 intragastric balloon , and   
 duodenal -jejunal endoluminal liner  
Other Medical  
12. Have renal impairment measured as estimated glomerular filtration rate (eGFR) 
<45 mL/min/1.73 m2, calculated by [INVESTIGATOR_82351] -Epi[INVESTIGATOR_623] (CKD -
EPI) as determined by [CONTACT_83337]  
13. Have a known  clinically significant gastric emptying abnormality (for example, 
severe gastroparesis or gastric outlet obstruction) or chronically take drugs that 
directly affect GI motility  
14. Have a history  of acute or chronic pancreatitis . A participant with a history of acute 
panc reatitis caused by [CONTACT_226384] a 
cholecystectomy to resolve the problem  
15. Have thyroid -stimulating hormone outside of the range of 0.4  to 6.0 mIU/L at 
screening visit  
Note : Participants receiving treatment for hypothyroidism may be included, provided 
their thyroid hormone replacement dose has been stable for at least 6 months.  
Note:  Thyroid -stimulating hormone  values above the normal range can, in some 
participant , suggest s ubclinical hypothyroidism. If, in the investigator’s opi[INVESTIGATOR_1649], the 
participant has subclinical hypothyroidism and may require initiation of thyroid 
hormone replacement during the study, the pa rticipant  should be excluded from the 
study.  
16. Have obesity  induce d by [CONTACT_57660] (for example, Cushing ’s 
syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, 
Melanocortin 4 Receptor  deficiency or Prader –Willi Syndrome)  
17. Have a history of significant active or unstable Major D epressive Disorder (MDD) or 
other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or 
other serious mood or anxiety disorder) within the last 2 years  
Note:  Participants  with MDD or generalized anxiety disorder whose disease state is 
considered stable for the past [ADDRESS_1077784] a  Patient Health Questionnaire -9 (PHQ -9) score of 15 or more at Visit 1  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 37 20. On the C -SSRS at Visit s 1, 3, or 4, prior to randomization : 
 a “yes” answer to Question 4 (Active Suicidal Ideati on with Some Intent to Act, 
Without Specific Plan) on the “Suicidal Ideation ” portion of the C -SSRS  
or  
 a “yes” answer to Question 5 (Active Suicidal Ideation with Specific Plan and 
Intent) on the “Suicidal Ideation ” portion of the C -SSRS  
or  
 a “yes” answer to any of the suicide -related behaviors (actual attempt, interrupted 
attempt, aborted attempt, preparatory act , or behavior) on the “Suicidal Behavior ” 
portion of the C -SSRS  
and  
 the ideation or behavior occurred within the past month  
21. Have uncont rolled hypertension (systolic BP above or equal to 160 mmHg and/or 
diastolic BP above or equal to 100 mmHg) . If a participant  is on anti-hype rtensive  
therapi[INVESTIGATOR_014], doses must be stable for [ADDRESS_1077785] an e levated resting pulse rate  (>100 bpm) at baseline  
23. Have any of the following cardiovascular conditions within 3 months prior to 
Screening : 
 acute myocardial infarction  
 cerebrovascular accident (stroke)  
 unstable angina, or  
 hospi[INVESTIGATOR_597962] (CHF)  
24. Ongoing or history of frequent intermittent or chronic tachyarrhythmia syndromes 
(such as atrial fibrillation, supraventricular tachycardia, and positional orthostatic 
tachycardia syndrome).  
Note:  Participants with history of premature atrial contractions or premature 
ventricular contractions may be included.  
25. Have NYHA Functional Classification III or IV CHF  
26. Have an electrocardiogram (ECG) considered by [CONTACT_783717] c disease or with abnormalities that may interfere with the interpretation of 
changes in ECG intervals at screening   
27. Have acute or chronic hepatitis, or signs  and symptoms of any other liver disease 
other than NAFLD, or any of the following, as determined by [CONTACT_783718] 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 38  ALT level >3.0 X upper limit of normal (ULN) for the reference range  
 alkaline phosphatase (ALP) level >1.5X ULN for the reference range, or  
 total bilirubin level (TBL) >1.5X ULN for the reference range (except for 
cases of known Gilbert’s Syndrome)   
28. Have a serum  calcitonin level (at Visit 1 ) of 
 ≥20 ng/L, if eGFR ≥60 mL/min/1.73 m2 or 
 ≥35 ng/L if eGFR <60 mL/min/1.73 m2 (as determined by [CONTACT_783719] 1 ) 
29. Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple 
endocrine neoplasia (MEN) syndrome type [ADDRESS_1077786] a history of an active or untreated malignancy or are in remission from a 
clinically significant malignancy (other than basal or squamous cell skin cancer, in 
situ carcinomas of the cervix, or in situ prostate cancer) for less than [ADDRESS_1077787] any other condition not listed in this section (for example, hypersensitivity or 
intolerance) that is a contraindication to GLP -1RA  
32. Have a history of any other condition (such as known drug or alcohol abuse, 
diagnosed eating disorder, or other psychiatric disorder) that, in the opi[INVESTIGATOR_1070], may preclude the participant from following and completing the protocol  
33. Alcohol consumption >14 units/week for women a nd >21 units/week for men  
34. Have a history of use of marijuana or tetrahydrocannabinol  (THC) -containing 
products within 3 months of enrollment or unwillingness to abstain from marijuana or 
THC -containing products use during the trial  
Note : If a participant h as used cannabidiol oil during the past [ADDRESS_1077788] had a transplanted organ (corneal transplants [keratoplasty] are allowed) or are 
awaiting an organ transpla nt 
36. Have any hematological condition that may interfere with HbA1c measurement (for 
example, hemolytic anemias and sickle cell disease)  
37. Have had a blood donation of [ADDRESS_1077789] a 
hemoglobin value <11  g/dL (males) or <10  g/dL (females), or any other condition 
known to interfere with HbA1c methodology  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077790] a history o f atopy (severe or multiple allergic manifestations) or clinically 
significant multiple or severe drug allergies, or intolerance to topi[INVESTIGATOR_11930], 
or severe posttreatment hypersensitivity reactions (including, but not limited to, 
erythema multifo rme major, linear immunoglobulin A dermatosis, toxic epi[INVESTIGATOR_7387], anaphylaxis, angioedema, or exfoliative dermatitis)  
39. Have a fasting serum triglyceride level of >500  mg/dL at screening. If a participant  is 
on lipid -lowering therapi[INVESTIGATOR_014], doses must b e stable for [ADDRESS_1077791] 2 years, defined by 
[CONTACT_783720]’s  physician; subjects who had a procedure to remove the 
gallstones and/or the gallbladder (cholecystectomy), with no long -term complications, 
are eligible for participation as long as the procedure was completed at least [ADDRESS_1077792] a h istory of documented human immunodeficiency virus (HIV) infection  
Prior/Concomitant Therapy  
43. Are receiving or have received within 3 months prior to screening chronic (>2 weeks) 
systemic glucocorticoid therapy (excluding topi[INVESTIGATOR_2855], intraocular, intranasal, single 
intraarticular  injection , or inhaled preparations) or have evidence of a significant, 
active autoimmune abnormality (for example, lupus or rheumatoid arthritis) that has 
required (within the last 3 months) or is likely to require, in the opi[INVESTIGATOR_1070], concurrent treatment with systemic glucocorticoids (excluding topi[INVESTIGATOR_2855], 
intraocular, intranasal, intraarticular, or inhaled preparations) during the course of the 
study  
44. Have current treatment with or history of treatment with (within 3 mon ths prior to 
screening) medications that may cause significant weight gain including , but not 
limited to , tricyclic antidepressants, atypi[INVESTIGATOR_16709], and mood stabilizers  
Examples:  
 imipramine  
 amitript yline  
 mirtazapin e 
 paroxetine  
 phenelzine  
 chlorpromazine  
 thioridazine  
 clozapi[INVESTIGATOR_050]  
 olanzapi[INVESTIGATOR_050]  
 valproic acid and its derivatives , and   
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 40  lithium . 
Note:  Selective serotonin reuptake inhibitors other than paroxetine are permitted .  
45. Have taken within 3 months prior to screening medications (prescribed or over the 
counter ) or alternative remedies intended to promote weight loss  
Examples include, but are not limited to:  
 Saxenda® (liraglutide 3.0 mg)  or other GLP -1RA 
 Xenical®/Alli® (orlistat)  
 Meridia® (sibutramine)  
 Acutrim® (phenylpropanolamine)  
 Sanorex® (mazindol)  
 Api[INVESTIGATOR_82335]® or LomairaTM (phentermine)  
 QsymiaTM (phentermine/topi[INVESTIGATOR_81063])  
 Contrave® (naltrexone/bupropi[INVESTIGATOR_2394])  
 
46. Use of metformin, or any other glucose -lowering medication, whether prescribed for 
polycystic ovarian syndrome or diabetes prevention is not permitted  
47. Have started implantable or injectable contraceptives , such as Depo Provera® and 
Nexplanon®, within [ADDRESS_1077793] 3 months  
Prior/Concurrent Clinical Study Experience  
48. Have known allergies to GLP -1R agonists  or LY3437943  
49. Are currently  enrolled in any other clinical study involving an investigational product  
(IP) or any other type of medical research judged not to be scientifically or medically 
compatible with this study   
50. Within  the last [ADDRESS_1077794] previously received LY3437943  as part of this study or any another study 
investigating LY3437943  
Other Exclusions  
58. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted  
59. Are Lilly employees  
Note : The inclusion and exclusion criteria numbered from 52  to 57 are part of J1I -MC-GZBF 
Addendum (1). So, in Section 5.2, the exclusion criteria continue with the next available number 
in the sequence from the l ast number in the protocol addendum (58 –59). 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 41 5.3. Lifestyle Considerations  
Throughout the study , participants  may undergo medical assessment s and review of compliance 
with re quirements  before continuing in the study. Participants will report to the clinical res earch 
site for safety assessments and will remain in the clinic until all procedures for that visit are 
complete and the investigator has deemed it safe to release the participant from the clinic. There 
will be no inpatient stays. In addition, participants  will report to the clinical research site for 
pharmacokinetic (PK) -specific visits.  
Meals/Diet – Participants will fast for at least 8 hours overnight prior to each in-person site  visit 
where fasting samples are drawn and when weight measurements are take n. 
Physical Activity – Participants will be advised to avoid strenuous exercise within 24 hours 
prior to each study site v isit. When certain study procedures are in progress at the site, 
participants may be required to remain supi[INVESTIGATOR_226351].  
Alcohol – Alcohol will not be permitted 8 hours prior to the study site visits, until the 
participant  has been discharged from the clinical research site.  
Blood Donation – Study participants should be instructed not to donate blood or blood products 
during the stu dy and for 8 weeks following the study.   
5.3.1.  Diet and Physical Activity  Counseling  
Study participants will receive diet and physical activity counseling , using a standardized 
approach , by a dietician/nutritionist  or a similar qualified healthcare professional , as specified  in 
the SoA (Section 1.3). Based on the counseling provided, participants should follow a healthy 
lifestyle plan throughout the course of the study  (HHS 2018; USDA and HHS 2020) . Refer to 
Section 10.7 (Appendix 7) for details of the diet and physical activity recommendations .  
To encourage adherence, it is recommended that a 3 -day diet and exercise diary be completed 
prior to each counseling visit. During each visit, the participant’s diet is reviewed and advice to 
maximize adherence is provided if needed.  
5.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study  but are 
not subsequently  enrolled  in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participant s to meet the Consolidated Standards of 
Reporting Trials (CONSORT)  publishing require ments and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any SAE .  
Individuals who do not meet the criteria for participation in this study (screen failures) may  be 
rescreened only once at the discretion of the investigator. Before rescreening is performed, th e 
participant  must sign a new ICF and receive a new identification number. If, in the opi[INVESTIGATOR_144086], an ineligible lab test result is the resul t of an error or exceptional  circumstance, then  
that parameter can be retested once without the participant having to be rescreened.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077795] study  drug SC in to the abdominal wall , alternating  between 4  sites 
weekly , that is  right and left upper quadrants and right and left lower quadrants , using the 
injection supplies provided . A caregiver may administer the injection  after appropriate training . 
A new syringe will be used for each injection.  The actual date, time, and  injection -site location 
of all dose administrations will be recorded in the study drug administration log  by [CONTACT_2416].  
6.2. Preparation/Handling/Storage/Accou ntability  
 The investigator or designee must confirm appropriate storage  conditions have 
been maintained during transit for all study drug received and any discrepancies 
are reported and resolved before use of the study drug. 
 Only participants enrolled in t he study may receive study drug. Only study 
personnel  may supply , prepare,  or administer study drug. All study drugs must be 
stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized  study personnel . 
 The investigator -authorized study personnel are  responsible for study drug 
accountability, reconciliation, and record maintenance ( that is , receipt, 
reconciliation, and fina l disposition records).  
 Further guidance and information for the final disposition of unused study drug 
interventions are provided in the study training materials.   
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is a double -blind study.  
Participant s who meet all criteria for en rollment will be randomly assigned  to 1 of the study 
treatment arms  at Visit 4. Assignment to treatment arms  will be determined by a 
computer -generated random sequence using an IWRS. Participant s will be randomly assi gned  in 
a 2:1:1:1:1:2:2 ratio (LY3437943  1 mg QW, LY3437943  4 mg QW (a),  LY3437943  4 mg QW 
(b), LY3437943 8 mg QW (a), LY3437943 8 mg QW (b), LY3437943 12 mg QW,  placebo  
QW).  
Although the participant and the investigator will know the injection volume of study drug , they 
will not know whether the participant is receiving LY 3437943  or placebo.  To preserve the blind, 
participa nts randomized to placebo wil l be randomly assigned to follow the injection dose 
schedule for 1 of the LY3437943 treatment  arms. 
To pr eserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is complete.  
Emergency unblinding may be performed through the IWRS.  This option may be used ONLY if 
the parti cipant’s well -being requires knowledge of  the participant’s treatment assignment. All 
unblinding events are recorded and reported by [CONTACT_8784] . 
If an investigator , site personnel performing assessments, or participant is unblinded, the 
participant must be d iscontinued from the study. In cases where there are ethical reasons to have 
the participant remain in the study, the investigator must obtain specific approval from a sponsor 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 44 clinical research physician (CRP)  or clinical research scientist (CRS)  for the  participant to 
continue in the study.  
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a participant’s treatment assignment is warranted for medical management of the event. The 
participant ’s safety mus t always be the first consideration in making such a determination. If a 
participant’s treatment assignment is unblinded, Lilly must be notified immediately. If the 
investigator decides that unblinding is warranted,  it is the responsibility of the investig ator to 
promptly document the decision and rationale and notify Lilly as soon as possible.   
6.4. Study Intervention Compliance  
Partic ipant compliance with study drug will be assessed at each visit. Compliance will be 
assessed by [CONTACT_783721]/or empty vials  returned. 
Study  drug compliance will be determined by [CONTACT_716]:  
 Study drug administration data will be recorded by [CONTACT_783722].  
 The participant s will be instructed to return any unused study  drug and/or empty 
vials  at the next visit to the study site for the purpose of performing drug 
accountability.  
Treatment  compliance will be assessed every [ADDRESS_1077796] 75% of the required  SC doses of study drugs.  
In additi on to the assessment of a participan t’s compliance with the study drug administration, 
other  aspects of compliance with the study treatments will be assessed at each visit based on the 
participant ’s adherence to the visit schedule, completion of study , study drug administration logs , 
and any other parameter s the investigator considers necessary.  
Participant s considered to be poorly compliant with their medication , and/or the study 
procedures will receive additional training and instruction, as required, and will be reminded of 
the importance of complying with the protocol.  Additional unscheduled visits may be scheduled 
if study site personnel determine that a participant requires additional training for the study drug 
preparation and injection techniques.   
6.5. Concomitant Therapy  
Investigative site staff will inform pa rticipants  that they must consult with the investigator or a  
designated site staff member upon being prescribed any new medications during the study. This  
may not be possible when initiated for treatment of medical emergencies, in which case, the  
participan t will inform the investigator or  a designated site staff member as soon as possible.  
Participants will be permitted to use concomitant medications that they require during the study, 
except certain medications (for example,  other medications for weight management) that may 
interfere wit h the assessment of efficacy and safety characteristics of the study treatments.  
Treatment with , or initiation of, medications that are excluded in the entry criteria (Section  5.2) 
is not permitted  during the study , except for  medications required for the management of 
incident diabetes  (see Section 6.5.2 ). Hormone replacement therapy in postmenopausal women 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 45 and contraceptives containing an estrogen and a progestin (oral or transdermal system) in 
premenopausal women  should not be started after entering the study. The sponsor should be 
contact[CONTACT_35114] a participant starts treatment with a medication that is pro hibited by [CONTACT_760] . 
Doses of other prescription medications for treatment of concurrent medical conditions should 
remain constant during the study unless an  adjustment is medically indicated . For example, doses 
of anti-hypertensive m edication may be reduced if the participant’s BP declines significantly 
during  the study resulting in symptoms of light headedness .  
Any medication or vaccine (including over -the-counter or prescription medicines and 
acetaminophen/paracetamol), vitamins, and/or herbal supplements that the participant is 
receiving at the time of enrollment or receives during the study must be recorded in the eCRF.  
Nonsteroidal anti -inflammatory medications (including ibuprofen and aspi[INVESTIGATOR_248]), acetaminophen, 
cough suppressants, antihistamines, antibiotics, and topi[INVESTIGATOR_783702] -
needed basis without notifying the sponsor and are not restricted by [CONTACT_3433] e stable dosing 
requirements listed earlier . Apart from these medications, the sponsor should be contact[CONTACT_783723]. If the need for additional concomitant 
medication arises, the partic ipant may be cont inued in the study -on-study  drug if, in the 
investigator’s opi[INVESTIGATOR_1649], the addition of the new medication does not pose a safety risk. If an 
additional concomitant medication is started, the sponsor should be informed as soon as possible.  
6.5.1.  Management of Partic ipants with Gastrointestinal Symptoms  
In the Phase [ADDRESS_1077797] reported TEAEs for participants receiving LY 3437943  were 
nausea, vomiting, and diarrhea. To mitigate GI symptoms and manage participants with 
intolerable GI AEs, the investigator should  
 Advise pa rticipants  to eat smaller meals, for example, splitting 3 daily meals into 4, or 
more smaller meals, and to stop eating when they feel full. Also, participants  may be 
informed that lower -fat meals could be better tolerated.  
 Prescribe symptomatic medication (for example, anti -emetic or antidiarrheal medication) 
per local country availability and individual participant  needs. Use of symptomatic 
medication should be captured as concomitant medication in the eCRF.  
 Temporarily interrupt study drug (omi t 1 dose ). Refer to Section 6.6.[ADDRESS_1077798] despi[INVESTIGATOR_10902] , see Section 6.6. 
6.5.2.  Definition and Management of In cident Diabetes  
Definition of Incident Diabetes  
Incident diabetes is defined when any 1 of the following occur s after randomization ( ADA 
2020): 
 In a participant  with classic symptoms of hyperglycemia or hyperglycemic crisis, a 
random serum  glucose ≥200 mg/dL (11.1 mmol/L)  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 46  Within a 4 -week period, any 2 of the following criteria are observed or 1 abnormal  value 
is observed and confirmed  
o HbA1c ≥6.5% (48 mmol/mol)  
o Fasting serum glucose  ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric 
intake for at least 8 h , and 
o Initiation of any medication for the treatment of diabetes . 
Management of Incident Type 2 Diabetes  
Participants who develop T2D during the study will be  
 provided and trained to use a glucometer  (the frequency of self -monit oring of BG will be 
at the discretion of the investigator)  
 educated on the signs and symptoms of hypoglycemia and its treatment, and  
 provided a diary to record hypoglycemic epi[INVESTIGATOR_261712] [IP_ADDRESS] . 
Participants will be referred to their usual care provider and provided with a letter showing the  
study results indicative of diabetes. The decision to initiate  glucose -lowering medication  and the 
choice of glucose -lowering medication  will be at the  discretion of the participant’s usual care 
provider, except for  the following medications that are not allowed in the study : 
 GLP -1RA, and  
 Dipeptidyl  peptidase -4 (DPP -4) inhibitors .  
GLP -1RA and DPP -4 inhibitors should not be used in combination with LY3437943  due to  
overlappi[INVESTIGATOR_783703].  Although metformin is 
not allowed upon study entry , it is allowed for treatment of incident T2D and is recommended 
for initial glucose -lowering therapy in this circumstance . Metformin should not be initiated  
during the study for the treatment of other metabolic conditions (for example, polycystic ovary  
syndrome and diabetes prevention).  If additional glucose -lowering therapy  beyond metformin  is 
needed t o treat incident T2D, sodium -glucose co -transporter -2 (SGLT -2) inhibitors , 
sulfonylureas , or long-acting basal insulin may be considered.  
Monitoring for hypoglycemia includes capture of events as defined  in Section [IP_ADDRESS] . Date of 
diagnosis of diabetes will be captured in the eCRF.  If participants are diagnosed with incident 
T1D, discontinuation of study drug should be considered as noted in Section 7.1.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 50 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
7.1. Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant to permanently discontinue (definitive 
discontinuation) study drug. If study drug is definitively discontinued, the participant  will remain 
in the study to be evaluated for  all pla nned efficacy and safety measures . In addition, the 
participant may continue to receive diet and physical activity counseling. Participants who are 
unwilling to attend all scheduled visits after stoppi[INVESTIGATOR_783704] a 
final visit  48 weeks after randomization, primarily for weight measurement and assessment of 
AEs (Visit 99). If participants are unwilling to attend Visit 99, their refusal to attend should be 
documented in the participant medical record. See the SoA for data to be c ollected at the time of 
discontinuation of study drug and follow -up and for any further evaluations that need to be 
completed.  
Possible reasons leading to permanent discontinuation of study drug : 
 participant decision  
o the participant requests to discontinue study drug  
 clinical considerations  
o initiation of prohibited concomitant medications (see Section 6.5) if 
participants will not or cannot discontinue them  
o intolerable GI symptoms despi[INVESTIGATOR_134053] 6.5.1  
and Section  6.6.1  
Note:  The investigator should contact [CONTACT_783724]/CRS  to discuss 
whether it is medically appropriate for the participant to continue study 
treatment.  
o if the investigator, after consultation with the sponsor -designated medical 
monitor, determines that a systemic hypersensitivity reaction has occurred 
related to study drug administration, the participant should be permanently 
discontinued from the investigational drug  
o BMI ≤1 9 kg/m2 is reached at any time during the treatment period  
o diagnosis of T1D  
o diagnosis of MTC or MEN2 after randomization  
o significant elevation of calcitonin (Section [IP_ADDRESS].1 )  
o diagnosis of acute or chronic pancreatitis  
o diagnosis of an active or untreated malignancy (other than basal or squamous 
cell skin cancer, in situ carcinomas of the cervix, or in situ prosta te cancer) 
after randomization  
o onset of pregnancy in a female participant  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 51 o occurrence of any other treatment -emergent AE (TEAE), SAE, or clinically 
significant finding for which the investigator believes that permanent study  
drug discontinuation is the app ropriate measure to be taken  
o PHQ -9 score ≥15  
▪ Participants should be referred to a Mental Health Professional (MHP) 
to assist in deciding whether the participant  should be discontinued 
from study drug. If a participant’s psychiatric disorder can be 
adequately treated with psycho - and/or pharmacotherapy, then the 
participant , at the discretion of the Investigator (in agreement with the 
MHP), may be continued in the  trial on randomized therapy.  
o in addition, study drug may be discontinued if participants  
▪ answered “yes” to either Question 4 (Active Suicidal Ideation with 
Some Intent to Act, Without Specific Plan) on the “Suicidal Ideation ” 
portion of the C -SSRS  
or  
▪ answered “yes” to Question 5 (Active Suicidal Ideation with Specific 
Plan and Intent) on the “Suicidal Ideation ” portion of the C -SSRS  
or  
▪ answered “yes” to any of the suicide -related behaviors (Actual 
attempt, Interrupted attempt, Aborted attempt, Prepar atory act or 
behavior) on the “Suicidal Behavior” portion of the C -SSRS.  
Note:  A psychiatrist or appropriately trained professional may assist in the decision to 
discontinue the participant.  
 discontinuation due to a hepatic event or liver test abnormality  
o Participants who are discontinued from study drug  due to a hepatic event or liver 
test abnormality should have additional hepatic safety data collected via eCRF.  
o Discontinuation of the study drug  for abnormal liver tests should be  considered 
by [CONTACT_783725] a participant meets 1 of the following conditions after 
consultation with the Lilly -designated medical monitor:  
▪ ALT or AST >8X ULN  
▪ ALT  >2X baseline value OR ≥300  U/L, whichever occurs first, if 
baseline ALT  ≥2X ULN  
▪ ALT or AST >5X ULN for more than 2 weeks  
▪ ALT or AST >3X ULN and TBL >2X ULN or international 
normalized ratio (INR) >1.5  
▪ ALT or AST >3X ULN with the appearance of fatigue, nausea, 
vomiting, right upper -quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 52 ▪ ALP >3X ULN  
▪ ALP >2.5X ULN and TBL >2X ULN  
▪ ALP >2.5X ULN with the appearance of fatigue, nausea, vomiting, 
right -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%) . 
Refer to Section 10.1.8  for discontinuation of specific sites or of the study as a whole.  
7.2. Participant Discontinuation/ Withdrawal from the Study  
A participant  may withdraw from the study  
 at any time at his  or her own request  
 at the request of his  or her designee (for example, parents or legal guardian)  
 at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
 if the participant becomes pregnant during the study   
 if enrollment in any other cli nical study involving an investigational product 
or enrollment in any other type of medical research judged not to be 
scientifically or medically compatible with this study , and  
 if the participant , for any reason, requires treatment with another therapeuti c 
agent that has been demonstrated to be effective for treatment of the study 
indication, discontinuation from the study occurs prior to introduction of the 
new agent . 
At the time of discontinuing from the study, if possible, an early discontinuation visit  should be 
conducted, as shown in the SoA. See SoA for data to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  The 
participant will be permanently discontinued both from the study i ntervention and from the study 
at that time.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
withdraws from the s tudy, he  or she may request destruction of any samples taken and not tested , 
and the investigator must document this in the site study records .  
7.3. Lost to Follow -Up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. Site personnel or designee are 
expected to make diligent attempts to contact [CONTACT_658095] f ail to return for a scheduled visit 
or were otherwise unable to be followed up by [CONTACT_779].   
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 53 8. Study Assessments and Procedures  
 Study procedures and their timing are summarized in the SoA.   
 Immediate  safety concerns  should be discussed with the s ponsor immed iately 
upon occurrence or awareness to determine if the participant should continue 
or discontinue study intervention . 
 Adherence to the study design requirements, including those specified in the 
SoA, is essential and required for study conduct.  
 All screen ing evaluations must be completed and reviewed to confirm that  
potential participant s meet all eligibility criteria. The investigator will 
maintain a screening log to record details of all participant s screened and to 
confirm eligibility or record reasons for sc reening failure, as applicable.   
8.1. Efficacy Assessments  
Primary:  
The primary efficacy measure is  body weight . Body weight measurements will be collected at 
specific clinic visits as summarized in the S oA. Methods for measuring body weight are 
described  in Section  10.8. 
Secondary:  
The following secondary efficacy  measures will be collected at the times shown in  the S oA. 
 BMI  (derived using body weight in kilograms divided by [CONTACT_134106] ), 
and 
 waist circumference  (see Section 10.8). 
Exploratory:  
The followi ng exploratory efficacy  measures will be collected at the times shown in  the SoA : 
 blood pressure  (see Section  [IP_ADDRESS] ) 
 heart rate  measured by [CONTACT_44117]  (see Section [IP_ADDRESS] ) 
 lipid parameters  
 glycemic control  
 mechanistic biomarkers related to insulin  sensitivity, pancreatic beta cell function, 
glucagon receptor target engagement, fatty acid oxidation, lipolysis, purine metabolism, 
cardiovascular risk, and inflammation  (see table in Appendix 10 [Section  10.10 ]), and  
 patient -reported outcomes  (see Section 10.11  [Appendix 11 ]). 
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the S oA. 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077799] circumference should be 
conducted according to SoA, and following the study -specific recommendations included in 
Section 10.8 (Appendix 8). 
A complete physical examination will include, at a minimum, assessments of  
• skin, including feet  
• cardiovascular  
• respi[INVESTIGATOR_696]  
• GI 
• neurological systems, and  
• thyroid exam.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
8.2.2.  Vital Signs  
For each participant, vital sign measurements should be conducted according to the SoA and 
following the study -specific recommendations included  in Section 10.8 (Appendix  8). 
Any clinically significant findings from vital sign measurement that result in a diagnosis and  that 
occur after the pa rticipant receives the first dose of study intervention should be reported to  Lilly 
or its designee as an AE via eCRF.  
8.2.3.  Electrocardiograms  
For each participant, a  12-lead ECG should be collected according to Section 1.3 (for details , 
please  see Section 10.8). Electrocardiograms will initially be interpreted by a qualified physician, 
the investigator, or  qualified designee at the site as soon after the time of ECG collection as 
possible, and ideal ly while the participant is still present, for immediate participan t management, 
should any clinically  relevant findings be identified. Any clinically significant findings from 
ECGs that result in a diagnosis and that occur after the participant receives t he first dose of the 
investigational treatment should be reported to Lilly or its designee as an AE via the eCRF.  In 
addition, tracings collected at the baseline, [ADDRESS_1077800].  
8.2.4.  Clinical Safety La boratory Assessments  
 See Section 10.2 (Appendix 2 ) for the list of clinical laboratory tests to be 
performed and to the So A for the timing and frequency.  
 The investigator must review the laboratory results , document this review, a nd 
report any clinically relevant changes occurring during the study as an AE . 
The laboratory results must be retained with source documents unless a 
Source Documen t Agreement or comparable document cites an electronic 
location that accommodates the expect ed retention duration. Clinically 
significant abnormal laboratory findings are those which are not associated 
with the underlying disease, unless judged by [CONTACT_134107] ’s condition.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077801] consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
Additional Hepatic Data Collection ( Hepatic Safety CRF) in Study Participants Who Have 
Abnormal Liver Tests during the Study  
Additional hepatic safety data collection in hepatic safety CRF s should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT to ≥[ADDRESS_1077802] on 2 or more consecutive blood tests (if baseline 
ALT <1.[ADDRESS_1077803])  
 In participants with baseline ALT ≥1.[ADDRESS_1077804], the threshold is ALT ≥3 X baseline on 
2 or more consecutive tests  
2. Elevated TBL to ≥[ADDRESS_1077805] (if baseline TBL <1.[ADDRESS_1077806]) (excep t for cases of known 
Gilbert’s syndrome)  
 In participants with baseline TBL ≥1.[ADDRESS_1077807], the threshold should be 
TBL  ≥2X baseline  
3. Elevation of serum ALP to ≥[ADDRESS_1077808] on 2 or more consecutive blood tests (if baseline 
ALP <1.[ADDRESS_1077809])  
 In participants with baseli ne ALP ≥1.[ADDRESS_1077810], the threshold is ALP ≥2 X baseline on 
2 or more consecutive blood tests  
4. Hepatic event considered to be a n SAE  
5. Discontinuation of study drug due to a hepatic event  
Note:  The interval between the [ADDRESS_1077811] obesity or are overweight are at increased risk for depression (Luppi[INVESTIGATOR_226356]. 2010). Depression can increase the risk for suicidal ideation and behavior. Therefore, study 
participants will be screened at trial entry and monitored during the stud y for depression, suicidal 
ideation, and behavior.  
Participants should be monitored appropriately for suicidal ideation and behavior or any other 
unusual changes in behavior, especially at the beginning and end of the course of treatment, or at 
the time of  dose changes, either increases or decreases. Consideration should be given to 
discontinuing the study medication in participants  who experience signs of suicidal ideation or 
behavior, following a risk assessment.  
Columbia Suicide -Severity Rating Scale (C -SSRS) is a scale that captures the occurrence, 
severity, and frequency of suicidal ideation and behavior during the assessment period via a 
questionnaire. The scale was developed by [CONTACT_17144] (NIMH) trial 
group (TASA) for the  purpose of being counterpart to the Columbia Classification Algorithm of 
Suicide Assessment (C -CASA) categorization of suicidal events.  
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 61 Event  Collection 
Start  Collection 
Stop  Timing for 
Reporting to 
Sponsor or 
Designee  Mechanism 
for 
Reporting  Back -Up 
Method of 
Reporting  
PC (after 
participant’s 
study 
participation 
has ended 
and the 
investigator 
becomes 
aware)   After 
participant’s 
study 
participation 
has ended  N/A Promptly  Product 
complaint 
form  N/A 
Abbreviations: AE  = adverse event; eCRF  = electronic case report form; N/A  = not applicable; PC  = product 
complaint; SAE  = serious adverse events . 
*Serious adverse events, including death, caused by [CONTACT_783726] . 
[IP_ADDRESS].  Adverse Event Monitoring with a Systematic Questionnaire  
Nonleading AE collection should occur prior to the collection of the C -SSRS.  
If a suicide -related event is discovered during the C -SSRS but was not captured during the 
nonleading AE collection, sites should not change the AE form.  
If an AE is serious or leads to discontinuation, it needs to be included on the AE form and the 
process for reporting SAEs is followed.  
8.3.2.  Adverse Events of Special Interest  
The following are adverse events  of special interest and will  be adjudicated by [CONTACT_783727]  (CEC) : 
 pancreatitis  
 major adverse cardiovascular events , and  
 deaths . 
The following are additional adverse events  of special interest for this program that will not be 
adjudicated by [CONTACT_783728]:  
 hypoglycemia  (Level 2 and 3)  
 thyroid malignancies and C -cell hyperplasia  
 supraventricular arrhythmias and cardiac conductive disorders  
 hypersensitivity events  
 injection site reactions  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 62  hepatobiliary disorders  
 severe GI AEs 
 antidrug antibodies  
 acute renal events , and  
 depression, suicidal ideation or behavior monitoring . 
Sites should collect additional details and data regarding these safety topi[INVESTIGATOR_1102] , as instructed on the 
applicable  eCRFs, and detailed below.  
[IP_ADDRESS].  Hypoglycemia  
Upon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia  
and how to treat hypoglycemia . Participants will be asked to contact s ite personnel if they 
experience any of these sym ptoms.  
Hypoglycemia may be identified by [CONTACT_11014]  
(whether confirmed or unconfirmed by [CONTACT_105419]) or by [CONTACT_644410] (BG)  
samples collected during study visits.  
All participants who develop incident diabetes during the study will be provided with 
glucometers.  Participants without diabetes may, at the investigator’s discretion, be given 
glucometers to assist  in the evaluation of reported symptoms consistent with hypoglycemia. 
Participants receiving  glucometers will be provided a diary to record relevant informat ion (for 
example, glucose values  and symptoms).  
Participants who develop incident diabetes during the study may be started on allowed glucose -
lowering medic ations  (Section 6.5.2 ). In the event that participants  subse quently develop  
persistent or recurrent unexplained hypoglycemia during the treatment period , participants  will 
be asked to reduce the dose or discontinue  any concomitant glucose -lowering medication  
commonly associated with hypoglycemia (for example, sulfonylurea or insulin).  
All hypoglycemic epi[INVESTIGATOR_134055] a specific eCRF and should not be recorded as 
AEs unless the event meets serious criter ia. If a hypoglycemic event meets severe criteria (see 
definition below), it should be recorded as serious on the AE and SAE eCRFs, and reported to 
Lilly as an SAE.  
Investigators should use the following definitions and criteria when diagnosing and categorizing 
an epi[INVESTIGATOR_10920] (the BG values in this section refer to values 
determined by a laboratory or International Federation of Clinical Chemistry and Laboratory 
Medicine blood -equival ent glucose meters and strips)  in accordance with the 2020 American 
Diabetes Association position statement on glycemic targets  (ADA 2020) . Level [ADDRESS_1077812] : 
Level 1 hypoglycemia:  
Glucose <70 mg/dL (3.9 mmol/L ) and ≥54 mg/dL (3.0 mmol/L):  Level [ADDRESS_1077813] -acting carbohydrates. Providers should 
continue to counsel partic ipants to treat hypoglycemia at this glucose alert value.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 63 Level 2 hypoglycemia : 
Glucose <54 mg/dL (3.0 mmol/L):  This is  also referred to as documented or BG-confirmed 
hypoglycemia  with glucose <54 mg/dL (3.0 mmol/L). This glucose threshold is clinically 
relevant regardless of the presence of absence of symptoms of hypoglycemia.  
Level 3 hypoglycemia:  
Severe hypoglycemia (in adults): A severe event characterized by [CONTACT_226405]/or 
physical status requiring assistance for treatment of hypoglycemia. For example, p articipants  
had altered  mental  status  and could not assist in the ir own care, or were  semiconscious or 
unconscious, or experienced  coma  with or without  seizures,  and the assistance of another 
person was needed to actively administer carbohydrate, glucagon, or other resuscitative  
actions.  Glucose  measurements  may not be available during  such an event, but neurological 
recovery  attributable to the restoration of  glucose concentration  to normal  is considered  
sufficient  evidence  that the event was induced by  a low glucose concentration.  
 The determination of a hypogly cemic event as an epi[INVESTIGATOR_66677], as 
defined above, is made by [CONTACT_598004] a 
participant simply having received assistance.  
 If a hypoglycemic event meets the criteria of severe hypoglycemia, the investigator 
must record the event as serious on the AE CRF and report it to Lilly as an SAE.  
Nocturnal hypoglycemia : 
Nocturnal hypoglycemia is  a hypoglycemia event (including severe hypoglycemia) that 
occurs at night  and presumably during sleep.  
To avoid duplicate reporting, all consecutive BG values <70 mg/dL (3. 9 mmol/L) occurring 
within a 1 -hour period may be considered to be a single hypoglycemic event 
(Weinberg  et al. 2010; Danne et al. 2013).  
[IP_ADDRESS].  Pancreatitis  
Diagnosis of Acute Pancreatitis  
Acute pancreatitis is an AE of interest in all studies with  LY3437943 , including this study. The 
diagnosis of acute pancreatitis requires 2 of the following 3 features  (Banks and Freeman 2006, 
Koizumi  2006) :  
 abdominal pain, characteristic of acute pancreatitis (that is, epi[INVESTIGATOR_543044], often associated with nausea and vomiting)  
 serum amylase (total, pancreatic, or both) and/or lipase ≥3X ULN , and  
 charact eristic findings of acute pancreatitis on CT scan or MRI.  
If acute pancreatitis is suspected, the investigator should  ensure that the following steps are 
taken:  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 64  obtain appropriate laboratory tests, including pancreatic amylase (p -amylase) and 
lipase , and  
 perform imaging studies, such as abdominal CT scan with or without contrast, or 
abdominal MRI . 
Note : Abdominal ultrasound may be used as an alternative method only if CT and 
MRI cannot be performed . 
 evaluate for possible causes of acute pancreatitis, including alcohol use, gallstone/gall 
bladder disease, hypertriglyceridemia, and concomitant medications . 
Discontinuation for Acute Pancreatitis  
If acute pancreatitis is suspected  by [CONTACT_093] , the participant must temporarily discontinue 
use of the  study drug . Afterwards, if the case is confirmed as acute pancreatitis by [CONTACT_398521], study drug  must be permanently discontinued ; the participant  may 
continue in the study. If the case is not confirmed, then the participant can restart study drug , if 
the investigator deems as clinically appropriate , as described in the Section 6.6. 
Case Adjudication and Data Entry 
An independent CEC will adjudicate all suspected cases of acute pancreatitis. Relevant data from 
participants with acute pancreatitis will be entered into a s pecifically designed  eCRF page. The 
adjudication committee representative will enter the results of adjudication in a  corresponding 
eCRF page.  
Asymptomatic Elevation of Pancreatic Amylase and/or Lipase  
Serial measures of pancreatic enzymes have limited clinical value for predicting epi[INVESTIGATOR_543045]  (Nauck et al. 201 7; Steinberg et al. 2017a, 
2017b). Therefore, further diagnostic follow -up of cases of asymptomati c elevation of pancreatic 
enzymes (lipase and/or p -amylase ≥3X ULN) is not mandated but may be performed based on 
the investigator’s clinical judgment and assessment of the participant’s overall clinical condition.  
[IP_ADDRESS].  Thyroid Malignancies and C -Cell Hyperplas ia  
Individuals with personal or family history of MTC and/or MEN -2 will be excluded from the 
study . Participants who are diagnosed with MTC and/or MEN -[ADDRESS_1077814].  
The assessment of thyroid safety during the trial will include reporting of any case of thyroid 
malignancy (including MTC , papi[INVESTIGATOR_10928] , and others ) and measurements of calcitonin. 
These  data will be captured in specific eCRFs. The purpose of calcito nin measurements is to 
assess the potential of LY3437943  to affect thyroid C -cell function, which may indicate 
development of C -cell hyperplasia and neoplasms.  
[IP_ADDRESS].1.  Calcitonin Measurements  
If an increased calcitonin value  (see definitions below) is observed in a participan t who has been 
administered a medication that is known to increase serum calcitonin , then  this medication 
should be stopped , and calcitonin levels should be measured after an appropriate washout period.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 65 For participan ts who require additional endocrine assessment because of increased calcitonin 
concentration as defined  in this section, data from the follow -up assessment will be collected in 
the specific section of the eCRF.  
Calcitonin Measurements in Parti cipants with eGFR ≥60 mL/min /1.73 m2  
A significant increase in calcitonin for participants with eGFR ≥60 mL/min/1.73 m2 is defined 
below. If a participant ’s lab oratory results  meet th ese criteria, these clinically significant 
laboratory results  should be recorded as an AE.  
 Serum calcitonin value ≥20 ng/L and <35 ng/L AND ≥50% increase from the screening 
value.  These participants will be asked to repeat the measurement within 1  month. If this 
repeat value is increas ing (≥10% increase), the study drug should  be stopped, and the 
participant s encouraged to undergo additional endocrine assessment and longer -term 
follow -up by [CONTACT_81124] a ny serious adverse effects  on the thyroid . 
 Serum calcitonin value ≥35 ng/L AND ≥50% over the screening value . In these 
participants , study drug should be stopped, and the participant s recommended to 
immediately undergo additional endocr ine assessments and longer - term follow -up by [CONTACT_81125].  
Calcitonin Measurement in Participants with eGFR <60 mL/min /1.73  m2  
A significant increase in calcitonin for participants with eGFR <60  mL/min /1.73  m2 is defined as 
a serum calcitonin value ≥35 ng/L AND ≥50% over the screening value. If a participant ’s labs 
meet th ese criteria, these clinically significant labs should be recorded as an AE.  
In these participants, study drug should be discontinued (after first confirming the value) and the 
participant s recommended to immediately undergo additional endocr ine assessments a nd longer -
term follow -up by [CONTACT_783729] . 
[IP_ADDRESS].  Major Adverse Cardiovascular Events  
Nonfatal cardiovascular  AEs will be adjudicated by a committee of physicians external to Lilly 
with cardiology experti se. This committee will be blinded to treatment assignment. The nonfatal 
cardiovascular  AEs to be adjudicated include  
 myocardial infarction  
 hospi[INVESTIGATOR_10929]  
 hospi[INVESTIGATOR_19934]  
 coronary interventions (such as coronary arte ry by[CONTACT_598009]), and  
 cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 66 [IP_ADDRESS].  Deaths  
All deaths will be adjudicated by a committee of physicians external to Lilly. This commi ttee 
will be blinded to treatment assignment . 
[IP_ADDRESS].  Supraventricular A rrhythmias and Cardiac Conduction Disorders   
Treatment -emergent cardiac conduction disorders will be further evaluated.  Participants  who 
develop any event from these groups of disorders should undergo an ECG , which should be 
submitted to the central reading center.  Additional diagnostic tests to determine exact diagnosis 
should be performed, as needed.  The specific diagnosis will be re corded as an AE. Events that 
meet criteria for serious conditions as described in Section  10.4 (Appendix 4 ) must be reported 
as SAEs.  
[IP_ADDRESS].  Hypersensitiv ity Reactions   
Many drugs, but particularly biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data describing each symptom should be provided 
to the sponsor in the eCRF.  
Sites should have appropri ately trained medical staff and appropriate medical equipment 
available when study participants  are receiving study drug . It is recommended that participants  
who experience a  systemic hypersensitivit y reaction be treated per  national and international 
guidelines.  
In the case of generalized urticaria  or anaphylaxis , additiona l blood and urine samples should be 
collected as described in Section 10.3 (Appendix 3). Laboratory results are provided to the 
sponsor via the central laboratory.  
[IP_ADDRESS].  Injection Site Reactions  
Symptoms of a local injection  site reaction may include erythema, induration, pain, pruritus, and 
edema. If an injection  site event is reported,  the AE will be recorded, and additional data will be 
provided to the sponsor in the eCR F. At the time of AE occurrence  of severe or serious types , 
samples will be collected for measurement of LY3437943  antidrug antibodies (ADAs) and 
LY3437943  concentration . 
[IP_ADDRESS].  Anti drug Antibodies  
The occurrence of ADA formation will be assessed as outlined in Section  8.9. 
[IP_ADDRESS].  Hepatobiliary Disorders  
All events of treatment -emergent (TE) biliary colic, cholecystitis, or other suspected events 
related to gallbladder disease should be evaluated and additional diagnostic tests performed, as 
needed.  In cases of elevated liver laboratory tests, hepatic mon itoring should be initiated as 
outlined in Section  [IP_ADDRESS] . 
[IP_ADDRESS].  Severe Gastrointestinal Adverse Events  
LY3437943 may cause severe GI AEs, such as nausea , vomiting, and diarrhea. Information 
about severe GI AEs as well as antiemetic/antidiarrheal use will be collected in the eCRF/AE 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 67 and Concomitant Medications form s, respectively . For detailed information concerning the 
management of GI AEs, please refer t o Section  6.5.1 . 
[IP_ADDRESS].  Acute Renal Events  
Renal safety will be assessed based on repeated renal functional assessment as well as 
assessment of AEs suggestive of acute renal failure or worsening of preexisting chron ic renal 
failure . Gastrointestinal AEs have been reported with LY3437943 , including nausea, diarrhea, 
and vomiting.  This is consistent with other GLP -1R agonists (Aroda and Ratner 2011). The se 
events may lead to dehydration, which could cause a deteriorati on in renal function, including 
acute renal failure.  Participants  should be advised to notify investigators in case of severe nausea, 
frequent vomiting, or symptoms of dehydration.  
[IP_ADDRESS].  Depression, Suicidal  Ideation , or Behavior Monitoring  
Participants will be monitored for depression and suicidal ideation or behavior through AE 
collection and by [CONTACT_10540] C -SSRS and the PHQ -[ADDRESS_1077815] be reviewed by [CONTACT_783730].  
Columbia Suicide -Severity Rating Scale (C -SSRS) is a scale that captures the occurrence, 
severity, and frequency of suicidal ideation and behavior during the assessment period via a 
questionnaire. The scale was developed by [CONTACT_17144] (NIMH) trial 
group ( TASA)  for the purpose of being counterpart to the Columbia Classification Algorithm of 
Suicide Assessment (C -CASA) categorization of suicidal events. For this study, the C -SSRS is 
adapted for the assessment of the ideation and behavior categories only. The Intensity of Ideation 
and Lethality of Behavior sections are removed.  
The PHQ9  questionnaire  is a validated, pa rticipant -completed  9-item depression module  of the 
Patient Health Questionnaire , which is  used as a diagnostic instrument for common mental 
disorders. The PHQ -9 consists of 9 items each scored on a scale of 0 = “not at all” to 3 = “nearly 
every day” with a recall period of “the last 2 weeks.” Major depression is diagnosed if [ADDRESS_1077816] “more than half the days” in the 
past 2 weeks, and 1 of the symptoms is depressed mood or anhedonia. As a severity measure, a 
higher score indicates greater severity.   
Participants will be referred to a MHP  if in the opi[INVESTIGATOR_783705]:  
 a PHQ -9 score ≥1 5 
 C-SSRS responses of  
o A “yes” answer to Question 4 (Active Suicidal Ideation with Some Intent to Act, 
Without Specific Plan)  on the “Suicidal Ideation ” portion of the C -SSRS  
or  
o A “yes” answer to Question 5 (Active Suicidal Ideation with Specific Plan and 
Intent) on the “Suicidal Ide ation ” portion of the C -SSRS  
or  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 68 o A “yes” answer to any of the suicide -related behaviors (actual attempt, interrupted 
attempt, aborted attempt, preparatory act , or behavior) on the “Suicidal Behavior ” 
portion of the C -SSRS 
8.4. Treatment of Overdose  
For this study, any total dose of study drug within a 48-hour time period greater than the dose 
prescribed by [CONTACT_783731] 10.4 (Appendix 4). 
In the event of an overdose, the investigator  should  
1. contact [CONTACT_27465]  
2. closely monitor the participant for any AE/SAE and laboratory abnormalities until  study drug 
can no longer be detected systemically (at least  30 days).  Refer to Section 8.[ADDRESS_1077817] dose of study 
drug if requested by [CONTACT_1689] (determined on a case -by-case b asis).  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_783732].  In the 
event of overdose, refer to the LY3437943 IB.  
8.5. Pharmacokinetics  
Blood samples for PK analyses will be collected from all randomized participants at the specified 
visits in accordance with SoA. Efforts should be taken to align clinical visits with PK sampling 
windows specified in the Pharmacokinetic Schedule of Events (Section 1.3). Otherwi se, 
participants may need to return to the clinical site for additional PK -specific visits to provide PK 
samples. O nly samples from participants assigned to treatment with LY3437943 will be analyzed 
for drug concentration.  
Date and time of each sample and the most recent LY3 [ADDRESS_1077818] participant visit for the study. During this time, 
samples remaining after the bioana lyses may be used for exploratory analyses , such as 
metabolism , protein binding , and/or bioanalytical cross -validation . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 69 8.6. Pharmacodynamics  
Pharmacodynamics assessments for LY 3437943  are included as part of the efficacy measures 
listed in Section 8.1 and will be collected in accordance with the SoA.  
8.7. Genetics  
A whole blood sample will be collected to enable exploratory pharmacogenetic analys es as 
specified in the SoA (Section  1.3), where local regulations all ow (see Section 10.6). 
Samples will not  be used to conduct unspecified disease or population genetic research either 
now or in the future. Samples may be used to investigate variable exposure or response to 
LY343 [ADDRESS_1077819] participant visit, or for a 
shorter period if local regulations and/or the ethica l review board impose shorter time limits, for 
the study at a facility selected by [CONTACT_81278]. This retention period enables use of new 
technologies, response to regulatory questions, and investigation of variable response that may 
not be observed until later in the development of LY3437943 or after LY3437943 is 
commercially available.  
Molecular technologies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or  exome 
sequencing, genome -wide association studies, multiplex assays, and candidate gene studies. 
Regardless of technology utilized, data generated will be used only for the specific research 
scope described in this section.  
8.8. Biomarkers  
Biomarker research i s performed on stored samples  to address questions of relevance to drug 
disposition, target engagement, PD, mechanism of action, variability of participant  response 
(including safety), and clinical outcome. Sample collection is incorporated into clinical s tudies to 
enable examination of these questions through measurement of biomolecules,  including 
deoxyribonucleic acid  (DNA ), ribonucleic acid (RNA ), proteins, lipi[INVESTIGATOR_805], and other cellular 
elements  (see Section 10.10 ).  
Serum and plasma samples for nonpharmacogenetic biomarker research will be collected at the 
times specified in the S oA (Section  1.3) where local regulations allow.  
Samples will be used for research on the drug target s, disease process, variable response to 
LY3437943, pathways associated with obesity, diabetes mellitus , and related clinical traits or 
complications, including nonalcoholic steatohepatitis, mechanism of action of LY3437943, 
and/or research method, or for validating diagnostic tools or assay(s) related to obesity, diabetes 
mellitus , or related clinical trait s or complications . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 70 All samples will be coded with the participant  number. These samples and any data generated 
can be linked back to the participant  only by [CONTACT_41417].  
Samples will be retained for a maximum of 15 years after the las t participant  visit, or for a 
shorter period if local regulations and/or ERBs/Institutional Review Boards impose shorter time 
limits, at a facility selected by [CONTACT_81278]. This retention period enables use of new 
technologies, response to regula tory questions, and investigation of variable response that may 
not be observed until later in the development of LY3437943, or after LY3437943 is 
commercially available.  
8.9. Immunogenicity Assessments  
At the visits and times specified in the SoA (Section  1.3), venous blood samples will be collected 
to determine antibody production against LY3437943 . Antibodies may be further characterized 
for cross -reactive binding to endogenous counterparts (native GIP, GLP -1, and glucagon), and 
their ability to neutralize the activity of LY3437943  and endogenous counterparts.  To interpret 
the results of immunogenicity, a venous blood  sample will be collected at the same time points  to 
determine the  concentrations of LY3437943 . All samples for immunogenicity should be taken 
predose when applicable and possible.  
Treatment -emergent ADAs are defined in Section [IP_ADDRESS] . If the immunogenicity sample at the 
last scheduled assessment or discontinuation visit is TE -ADA positive, additional samples may 
be taken until the ADA signal returns t o baseline ( that is,  no longer indicates TE-ADA)  or up to 
[ADDRESS_1077820] dose . A PK sample may be collected at each time point at the investigator’s 
discretion.  
Samples will be retained for a maximum of [ADDRESS_1077821] participant  visit, or for  a 
shorter period if local regulations and ERBs allow,  at a facility selected by [CONTACT_456]. The 
duration allows the sponsor to respond to future regulatory requests related to the LY3437943 . 
Any samples remaining after 15 years will be destroyed .  
8.10. Health  Economics  
This section is not applicable for this study.  
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077822] obesity or are overweight with 
weight -related comorbidities . 
9.2. Sample Size Determination  
Approximately 300 participants  will be randomly assigned  to LY3437943  1 mg, LY3437943  4 
mg (a), LY3437943  4 mg (b),  LY3437943  8 mg (a), LY3437943  8 mg (b) , LY3437943  12 mg or 
placebo with a 2:1:1:1:1: 2:2 ratio.  Assuming a 20% dropout rate , approximately 48 participants  
will complete  each LY3437943  dose and placebo . An upper limit of 60% enrollment of women 
will be used to ensure a sufficiently large sample of men.  
Sample size selection is guided by [CONTACT_783733]3437943 
dose to placebo relative to the percent change in body weigh t from baseline to Week 24. The 
evaluation of superiority to placebo will be conducted for each of the [ADDRESS_1077823] deviation (SD)  of 
10%, the LY3437943  group mean percen t change in body weight  at Week 24 from baseline 
compared to placebo  is assumed to be -8%. The chosen sample size provides  at least  97% power 
to establish superiority of LY3437943  1 mg, LY3437943  4 mg, LY3437943 8 mg, or 
LY3437943  12 mg compared  to placebo.  No adjustment for multiplicity will be performed.   
In addition, this sample size provides approximately 83% power to show that at least [ADDRESS_1077824] circumference compared with placebo at 
Week 24 and a SD of 9.6 cm.  
9.3. Populations for Analyses  
For purposes of analysis, the following analysis sets  are defined:  
Analysis Set  Description  
Entered  All participants who sign the ICF . 
Randomized  All participants who are randomly assigned to a treatment arm.  
Efficacy analysis set   Data obtained during treatment period from all randomly 
assigned  participants who take at least [ADDRESS_1077825] 1 dose of double -blind 
study treatment, regardless of adherence to study drug . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077826] 
1 dose of double -blind study treatment, regardless of adherence 
to study drug. Participants will be analyzed according to the 
treatment group to which they were randomly  assigned .  
 
9.4. Statistical Analyses  
9.4.1.  General Considerations  
Statistical analysis of this study will be the responsibility of Sponsor or its designee.  
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making th e change, will be described 
in the statistical analysis plan (SAP)  and the CSR . Additional exploratory analyses of the data 
will be conducted as deemed appropriate.  
All tests of treatment effects will be conducted at a 2 -sided alpha level of 0.05, unless o therwise 
stated, and all confidence intervals (CIs) will be given at a 2 -sided 95% level.  In statistical 
summaries and analyses, participants will be analyzed as randomized.  
The primary estimand of interest in comparing efficacy of LY3437943 doses with pla cebo for 
this study is the “efficacy ” estimand, which represents the efficacy prior to discontinuation of 
study drug. The primary efficacy assessment, guided by [CONTACT_941] “efficacy ” estimand, will be 
conducted using the efficacy analysis set. The “treatment -regimen” estimand , which  represents 
the efficacy irrespective of adherence to study drug , may also be used to compare  the primary  
efficacy of LY3437943 doses with placebo . The analysis guided by [CONTACT_941] “treatment -regimen” 
estimand will use  the full analysis set . Additional exploratory analyses for p articipants  who can 
comply with treatment of LY3437943 based on principal stratification may be performed.  
Details will be provided in the SAP.  
The summary statistics for continuous measures will include sample size, me an, SD, median, 
minimum, and maximum. The analysis model to make comparisons among treatment groups 
relative to continuous measurements assessed over time (in addition to the baseline and end of 
treatment measurements) will be a mixed model for repeated me asures (MMRM ). Analysis of 
covariance ( ANCOVA ) may be used to make comparisons among treatment groups for 
continuous measurement s with only [ADDRESS_1077827] -baseline assessment . 
Summary statistics for categorical measures (including categorized continuous measures) will 
include sample size, frequency, and percentages. Fisher’s exact test will be used to examine the 
treatment difference in categorical outcomes. Logistic regression may be used to examine the 
treatment difference in binary efficacy outcomes. The negativ e binomial regression model may 
be used for the treatment comparison of discrete count measures if deemed appropriate. 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 73 Participant -specific random effects may be added to the logistic and the negative binomial 
regression model s if longitudinal measurements  are available.  
Other statistical methods may be used, as appropriate, and details will be documented in the 
SAP.  
9.4.2.  Treatment Group Comparability  
[IP_ADDRESS].  Participant  Disposition  
Frequency counts and percentages of all participants  screened, randomized, and receiving at least 
1 dose of study drug will be presented by [CONTACT_783734] . A 
listing of randomized participants not receiving study drug will be provided.  All participants who 
discontinue the stu dy will be identified, and the extent of their participation in the study will be 
reported. If known, a reason for their discontinuation will be given. The  primary reasons for 
discontinuation will be listed and will be summarized by [CONTACT_3148]. The  percenta ge of 
participants  discontinuing from each treatment will be compared using the Fish er’s exact test.  
Kaplan –Meier analyses of time from randomization to premature discontinuation from study and 
premature discontinuation from study drug by [CONTACT_1570] w ill be provided.  
[IP_ADDRESS].  Participant Character istics  
Demographics, baseline characteristics, medical history, and concomitant illness will be 
summarized by [CONTACT_783735] .  
[IP_ADDRESS].  Concomitant Therapy  
Concomitant medications will be summarized by [CONTACT_783736] .  
[IP_ADDRESS].  Treatment  Compliance  
Treatment compliance is defined as taking at least 75% of required injections of study drug  
during the treatment period  while on  study drug . Frequency counts and percentages of 
participants  compliant to study drug will be summarized by  [CONTACT_783737] .  
9.4.3.  Primary Endpoint (s) 
The efficacy analyses for the primary  endpoint  will b e conducted to establish superiority of 
LY3437943 [ADDRESS_1077828] to mean percent change of body weight  from randomization ( Week 0)  to Week 24.  
The primary efficacy analysis will be guided by  [CONTACT_941] “efficacy ” estimand and conducted using the 
efficacy analysis set. The primary analyses model  will be a MMRM with treatment, visit, and 
treatment -by-visit interaction as fixed effects, baseline body weight  at randomization (Week 0)  
and sex as covariat es, and participant as a random effect. Additional covariates may be added 
and will be detailed in the SAP. 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 74 9.4.4.  Secondary Endpoint (s) 
[IP_ADDRESS].  Efficacy Analyses  
The following secondary  endpoints  will be analyzed on the efficacy analysis set : 
 mean percent change of body  weight  from randomization (Week 0)  to Week 48 
 percentage  of study participants who achieve the following criteria from randomization 
(Week 0)  at Weeks 24 and 48: 
o ≥5% body weight reduction  
o ≥10% body weight reduction , and   
o ≥15% body weight reduction  
 mean change in body weight (kg) from randomization (Week 0) at Weeks 24 and 48  
 mean change in BMI (kg/m2) from randomization (Week 0) at Weeks 24 and 48, and  
 mean c hange in waist circumference (cm)  from randomization (Week 0) at Weeks 24 and 
48. 
Analyses of continuous endpoints, including change in body weight (kg) , BMI (kg/m2), and 
waist circumference (cm),  will be conducted in a manner similar to the primary efficacy analyses 
discussed in Section 9.4.2 . 
Analyses for p ercentage s of participants reaching ≥5% body weight reduction, ≥10% body 
weight reduction, and ≥15% body weight reduction  from baseline at Weeks 24 and 48 will be 
conducted usin g a longitudinal logistic regression model with treatment, visit, and treatment -by-
visit interaction as fixed effects, baseline values  at randomization (Week 0)  and sex as 
covariates, and participant as a random effect.  Missing body weight data at Weeks [ADDRESS_1077829] before conducting the analyses.  Additional secondary efficacy analyses 
may be performed, if deemed necessary. The details will be provided in the SAP.  
[IP_ADDRESS].  Safety Analyses  
Unless specified otherwise, safety assessments will be guided by [CONTACT_170255]3437943 doses with placebo irrespective of adherence to study drug. Thus, safety analyses 
will be conducted using the full analysis set.  
Adverse events will be coded from the actual term using the Medical Diction ary for Regulatory 
Activities (MedDRA) and reported with preferred terms and system organ class. Summary 
statistics will be provided for incidence of TEAEs, SAEs, study discontinuation due to AEs, 
study drug discontinuation due to AEs, deaths, and other CV  endpoints. Counts and proportions 
of participants  experiencing AEs will be reported for each treatment group  and each dose 
escalation subgroup , and Fisher’s exact test will be used to compare the LY dose groups  with 
placebo . 
[IP_ADDRESS].  Central Laboratory Measures, V ital Signs, and Electrocardiograms  
Values and change from baseline to postbaseline values of central laboratory measures, vital 
signs, and selected ECG parameters will be summarized  for each treatment group  at each 
scheduled visit. The details will be prov ided in the SAP.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 75 [IP_ADDRESS].  Evaluation of Immunogenicity  
The frequency and percentage of participants  with preexisting ADA and with treatment -
emergent  ADA+ to LY3437943  may be tabulated. Treatment -emergent ADA are defined as 
those with a titer 2 -fold (1 dilution) gr eater than the minimum required dilution if no ADAs were 
detected at baseline (treatment -induced ADA) or those with a 4 -fold (2 dilutions) increase in titer 
compared to baseline if ADAs were detected at baseline (treatment -boosted ADA). For the 
treatment -emergent  ADA+ participants , the distribution of maximum titers may be described. 
The frequency of neutralizing antibodies  against LY3437943 , if performed, may be tabulated in 
treatment -emergent  ADA+ participants . If cross -reactivity to native GLP -1, GIP, and glucagon  
or neutralizing antibodies against native GLP -1, GIP, and glucagon  assays are performed, the 
frequency of each may be reported.  
The relationship between the presence of antibodies and the PK parameters and PD response 
including safety and effi cacy to LY3437943  may be assessed.  
9.4.5.  Exploratory Endpoint s 
Details will be provided in the SAP.  
9.4.6.  Other Safety Analyse s 
Other safety analyses may be conducted , if deemed necessary. Details  will be provided in the 
SAP.  
9.4.7.  Other Analyses  
[IP_ADDRESS].  Analysis of PHQ -9 Data  
Specific diagnostic symptoms that determine the presence of a clinical depressive disorder per 
the Diagnosis and Statistical Manual for Mental Disorders will be summarized base d on 
response s to the PHQ -9 question naire (Kroenke et al. 2001, Moriarty et al. 2015) . Details will be 
provided in SAP.   
[IP_ADDRESS].  Analysis of C -SSRS Data  
Suicide -related thoughts and behaviors occurring during treatment will be summarized based on 
responses to the C -SSRS consistent with the C -SSRS Scoring and Data Analysis Guide (C -SSRS 
WWW).  Details will be provided in SAP.  
9.4.8.  Pharmacokinetic/Pharmac odynamic Analyses  
LY3437943 concentration data will be summarized and analyzed using a population PK 
approach via nonlinear mixed -effects modeling. The relationships between LY3437943 dose 
and/or concentration and selected efficacy, tolerability, and safety endpoints may be 
characterized. Additionally, the impact of intrinsi c and extrinsic factors , such as age, weight, 
gender, and renal function on PK and/or PD parameters , may be examined as needed. If  ADA  
titers are detected from immunogenicity testing, then the impact of immunogenicity titers on 
LY3437943 PK or any relevant  PD parameters may also be examined.  Additional analyses may 
be conducted if they are deemed appropriate. Further details on PK and PK/PD analyses will be 
provided in the PK/PD analysis plan.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 76 9.5. Interim Analyses  
No interim analyses are planned for this study . Unplanned interim analyses may be performed as 
necessary  if a safety concern is identified from  review of  blinded data . In the event an interim 
analysis is conducted , both efficacy and safety data will be reviewed to a ssess  the balance of 
benefit and risk .  
If there are unplanned interim  analyses, an assessment committee ( AC) will be formed to review 
the interim analyses in an unblinded manner.  The details regarding number of participants  and 
type of analysis will be provide d in the AC charter. Study team members who have potential 
contact [CONTACT_693125]. Information that may unblind the 
study during the analyses will not be reported to study sites or blinded study team members 
before the study has been unblinded. Study sites will receive information about interim results 
only if deemed necessary for the safety of the participants.  
The primary database lock and primary data analysis for Study GZB F may occur when all 
participants  have completed [ADDRESS_1077830] completed 48 weeks of 
treatment and the 4 -week follow -up period.  Unblinded data and results will not b e shared with 
the study sites in  order to maintain blinding at the site s while the study is still ongoing.  Details 
will be specified in the blinding/unblinding plan and in the AC charter.  
The addition of an interim analysis can be determined at any time du ring the study and will not 
result in  a protocol amendment.  
9.6. Data Monitoring Committee (DMC)   
Not applicable . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 77 10. Supporting Documentation and Operational Considerations  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1.  Regulatory and Ethical  Considerations  
● This study will be conducted in accordance with the protocol and with the 
following:  
○ Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of  
Medical Sciences (CIOMS) International Ethical Guidelines  
○ Applicable International Council for Harmonization (ICH) Good Clinical 
Practice (GCP) Guidelines  
○ Applicable laws and regulations  
● The protocol, protocol amendments, ICF, Investigator Brochure,  and other 
relevant documents ( for example , advertisements) must be submitted to an 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) by [CONTACT_52009]/IEC  before the study is 
initiated.  
● Any amen dments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC  
○ Notifying the IRB/IEC of SAEs  or other significant safety findings  as required 
by [CONTACT_1744]/IEC procedures  
○ Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 C ode of Federal Regulations (C FR), ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clini cal studies (if 
applicable), and all other applicable local regulations  
● Investigator sites are compensated for participation in the study  as detailed in the 
clinical trial agreement . 
10.1.2  Informed Consent Process  
● The investigator or his  or her representativ e will explain the nature of the study , 
including the risks and benefits,  to the participant or his  or her legally authorized 
representative and answer all  questions regarding the study.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 78 ● Participants must be informed that their participation is voluntary . Participants or 
their legally authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_1077831] (HIPAA) 
requirements, where applicable, and the I RB/IEC or study center.  
● The medical record must include a statement that written informed consent was 
obtained before the participant was enter ed in the study and the date the written 
consent was obtained. The authori zed person obtaining the informed consent must 
also sign the ICF.  
● Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
● A copy of the ICF(s) must be provided to the participant or the participant’s 
legally authorized representati ve and is kept on file .  
Participants who are rescreened are required to sign a new ICF  and receive a new identification 
number . 
10.1.3  Data Protection  
● Participants will be assigned a unique identifier by [CONTACT_456] . Any participant 
records , datasets  or tissue samples  that are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant identi fiable will not be transferred.  
● The participant must b e informed that his  or her personal study -related data will 
be used by [CONTACT_10999]. The level of 
disclosure must also b e explained to the participant  who will be required to give 
consent for his or her data to b e used as described in the informed consent .  
● The participant must be informed that his  or her medical records may be 
examined by [CONTACT_454589], by [CONTACT_6667]/IEC members, and by [CONTACT_57764].  
● The sponsor has processes in place to ensure data protection, information security 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event  of a data security breach.  
10.1.4  Committees Structure  
An independent CEC  will be formed to adjudicate major adverse cardiovascular events , deaths , 
and pancreati tis AEs, as specified  in Section  8.3.2 .  
10.1.5  Dissemination of Clinical Study Data  
Required clinical trial registries (for example, ClinicalTrials.gov) will be updated with the results 
from registered clinical trials regardless of the research outcome in accordance with local laws 
and regulations.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 79 All CSRs, amendments , and addenda will be submitted to external regulatory authorities, 
external partners (as applicable) and sites.  
The publication policy for Study G ZBF is outlined  in Section 10.1.9  and further described in the 
Clinical Trial Agreement (CTA ). 
10.1.6  Data Quality Assurance  
● All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically ( for example , 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
● The investigator must maintain accurate documentation (source data) that 
supports the inf ormation entered in  the CRF.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source data 
documents.  
● Monitoring details describing strategy ( for example , risk -based initiatives in 
operations and quality , such as risk management and mitigation strategies and 
analytical risk -based monitori ng), methods, responsibilities , and requirements, 
including handling of noncompliance issues and monitoring techniques , are 
provided in the Monitoring Plan.  
● The sponsor or designee is responsible for the data management of this study , 
includin g quality checking of the data.  
● The sponsor assumes accountability for actions delegated to other individuals ( for 
example , contract res earch organizations ). 
● Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of particip ants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regu latory requirements.  
● Records and documents, including signed ICFs, pertaini ng to the conduct of this 
study must be retained by [CONTACT_695475] a longer retention period. 
No records may be destroyed during the retention period witho ut the written 
approval of the sponsor. No records may be transferred to another location or 
party without written notification to the sponsor . 
● In addition, Sponsor  or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be audited by [CONTACT_52011], and/or regulatory agencies at 
any time. Investigators will be given notice before an audit occurs . 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 80 Data Capture System  
The investigator is responsible  for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.   
An electronic data capture  (EDC)  system will be used in this study for the collection of CRF 
data. The investigator maintains a separate source for t he data entered by [CONTACT_82413] -provided EDC system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by [CONTACT_300986] g the CRF . 
Additionally, clinical outcome assessment data ( participant /clinician -focused outcome 
instrument ) will be collected by [CONTACT_47991] /authorized study personnel , via a paper source 
document and will be transcribed by [CONTACT_783738] . 
Data collected via the sponsor -provided data capture system  will be  stored at third  party. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system . Prior to decommissioning, the investigator will receive an archival 
copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system , and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the Sponsor  data 
warehouse.  
Data from complaint forms submitted to Sponsor  will be encoded and stored in the global 
product compla int management system.  
10.1.7  Source Documents  
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
● Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. A lso, current medical records must be 
available.  
● Definition of what constitutes source data can be found in  study training material .  
10.1.8  Study and Site Start and Closure  
[IP_ADDRESS]  Discontinuation of the Study  
The sponsor designee reserves the right to terminate the study at any time for any reason at the 
sole discretion of the sponsor. The study will be discontinued if Lilly or its designee  judges it 
necessary for medical, safety, regulatory, or other reasons consistent wi th applicable laws, 
regulations, and GCP.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 81 Medical Oversight and Safety Review  
Ongoing safety review(s) by [CONTACT_598017]. Such 
reviews will include  
 monitoring and assessing the safety information collected dur ing the trial both in real 
time and periodically  
 reviewing safety data for trends that need action , and   
 detecting adverse drug/device effects.  
A safety investigation will be triggered to determine if the study should be terminated early 
based on the foll owing criteria  
 two study participants develop the same TEAE or SAE considered possibly or probably 
related to study drug that is s evere or medically significant but not immediately life -
threatening; or where hospi[INVESTIGATOR_783706]; or 
is disabling; or limits self -care activities of daily living  
 one study participant develops any TEAE or SAE regardless of attribution to study drug 
that has l ife-threatening consequences or requires urgent intervention  
 death of any study participant at any time , and  
 any other clinically significant safety signal . 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract researc h organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the participant and assures 
appropriate participant therapy and/or follow -up. 
[IP_ADDRESS]  Discontinuation of Study Sites  
The sponsor designee reserves the right to close the study site at any time for any reason at the 
sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is 
considered closed when all requ ired documents and study supplies have been collected and a 
study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]  
● failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, th e sponsor ’s procedures, or GCP guidelines  
● inadequate recruitment of participants by [CONTACT_093] , and  
● discontinuation of further study intervention development.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 82 10.1.9  Publication Policy  
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal . 
10.1.[ADDRESS_1077832] a physic ian designated either as a principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a 
sub-investigator to provide necessary medical oversight of pa rticipant  care.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 88 Abbreviations: ADA = antidrug antibody; IgE = immunoglobulin E; IL = interleukin; PK = pharmacokinetic .   Complement (C3, C3a, and 
C5a)  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigative sites.  
   Cytokine panel (IL‐6, IL‐
1β, and IL‐10)  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigative sites.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 98  combined contraceptive vaginal ring, or  
 intrauterine devices . 
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical 
sponges , and  
 barrier method with use of a spermicide  
o condom with spermicide  
o  diaphragm with spermicide, or  
o female condom with  spermicide . 
 
Note:  The barrier method must include use of a 
spermicide ( that is , condom with spermicide, 
diaphragm with spermicide, female condom with 
spermicide) to be considered effective.  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, symptothermal)  
 withdrawal  
 post coital douche , and  
 lactational amenorrhea . 
Collection of Pregnancy Information  
Male Participants wi th Partners Who Become Pregnant  
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This applies only to randomized male p articipants who receive  study 
drug.  
● After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the 
appropriate form and submit it to the sponsor within 24 hours  of learning of the 
partner’s pregnancy. The female partner will also be followed to determine the 
outcome of the pregnancy. Information on the status of the mother and child will 
be forwarded to the sponsor. Generally, the follow -up will be no longer than 6  to 
8 weeks following the estimated delivery date. Any termination of the pregnancy 
will be reported regardless of fetal status (presence or absence of anomalies) or 
indication for the procedure.  
Female Participants Who Become Pregnant  
● The investigator w ill collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial information 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours  of learning of a participant ’s pregnancy.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 99 ● The participant will be followed up to determine the outcome of the pregnancy. 
The investigator will collect follow -up information on the participant and the 
neonate , and the information will be forwarded to the sponsor. Generally, follow -
up will not be required for longer than 6 to 8 weeks beyond the estimated delivery 
date. Any termination of pregnancy will be reported , regardless of fetal status 
(presence or absence  of anomalies) or indication for the procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion  (occurring at <2 0 weeks gestational age) or still birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such.  
● Any post -study pregnancy -related SAE considered reasonably related to the study 
interventio n by [CONTACT_465222] . While the investigator is not obligated to actively seek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting.  
● Any femal e participant who becomes pregnant while participating in the study 
will discontinue study  drug. If the participant is discontinued from the study drug, 
follow the standard discontinuation process for each study period.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 100 10.6. Appendix  6: Genetics  
Use/Analysis of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distri bution, metabolism, and excretion; mechanism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a  blood sample will be 
collected for DNA analysis from consen ting participants.  
● DNA samples may be used for research related to LY3437943 or obesity, diabetes 
mellitus, and related clinical traits or complications, including nonalcoholic 
steatohepatitis and related diseases. They may also be used to develop 
tests/ assays , including diagnostic tests related to LY3437943 , study interventions 
related to this drug class , or obesity, diabetes mellitus, and related clinical traits or 
complications, including nonalcoholic steatohepatitis . Genetic research may 
consist of the analysis of 1 or more candidate genes , the analysis of genetic 
markers throughout the genome , or analysis of the entire genome . 
● The samples may be analyzed as part of a multi -study assessment of genetic 
factors involve d in the response to  LY3437943  or study interventions related to 
this class to understand study disease or related conditions.  
● The results of genetic analyses may be reported in the CSR or in a separate study 
summary.  
● The sponsor will store the DNA sam ples in a secure storage space with adequate 
measures to protect confidentiality.  
● The samples will be retained while research on  LY3437943 or obesity, diabetes 
mellitus, and related clinical traits or complications, including nonalcoholic 
steatohepatitis , continues but no longer than  15 years or other period as per local 
requirements.   
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 101 10.7. Appendix 7: Diet and Physical Activity Counseling  
10.7.1  Diet 
For this study, c ounseling on a healthy diet will be based on the Dietary Guidelines for 
Americans 2020 -2025  published by [CONTACT_941] U.S. Department of Agricultur e and the U.S. Department 
of Health and Human Services  (USDA and HHS 2020) . The following principles form the basis 
of these guideline s. 
 “Customize and enjoy nutrient -dense food and beverage choices to reflect  personal 
preferences, cultural traditions, and budgetary considerations.  
o A healthy dietary pattern can benefit all individuals regardless of age, race, or 
ethnicity, or current health  status. The Dietary Guidelines  provides a framework 
intended to be customized to individual needs and  preferences, as well as the 
foodways of the diverse cultures in the [LOCATION_002]. ” 
 “Focus on meeting food group needs with nutrient -dense foods and beverages,  and stay 
within calorie limits.  
o An underlying premise of the Dietary Guidelines  is that nutritional needs should 
be met primarily from  foods and beverages —specifically, nutrient -dense foods 
and beverages. Nutrient -dense foods provide  vitamins, minerals, and other health -
promoting  components and have no or little added sugars, saturated  fat, and 
sodium. A healthy dietary pattern consists of nutrient -dense forms of foods and 
beverages across  all food groups, in recommended amounts, and within calorie 
limits.  
o The core elements that m ake up a healthy dietary pattern include:  
▪ Vegetables of all types —dark green; red and orange; beans, peas, and 
lentils; starchy; and  other vegetables  
▪ Fruits , especially whole fruit  
▪ Grains , at least half of which are whole grain  
▪ Dairy , including fat -free or  low-fat milk, yogurt, and cheese, and/or 
lactose -free versions and fortified  soy beverages and yogurt as alternatives  
▪ Protein foods , including lean meats, poultry, and eggs; seafood; beans, 
peas, and lentils; and nuts,  seeds, and soy products  
▪ Oils, includ ing vegetable oils and oils in food, such as seafood and nuts ” 
 “Limit foods and beverages higher in added sugars, saturated fat, and sodium, and  limit 
alcoholic beverages. ” 
o “Meeting food group recommendations —even with nutrient -dense choices —
requires most  of a person’s daily calorie needs and sodium limits. A healthy 
dietary pattern doesn’t have much room for  extra added sugars, saturated fat, or 
sodium —or for alcoholic beverages. A small amount of added sugars,  saturated 
fat, or sodium can be added to nutr ient-dense foods and beverages to help meet 
food group  recommendations, but foods and beverages high in these components 
should be limited. Limits are: ” 
▪ Added sugars —Less than 10 percent of calories per day  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 102 ▪ Saturated fat —Less than 10 percent of calories per day  
▪ Sodium —Less than 2,300 milligrams per day  
▪ “Alcoholic beverages —Adults of legal drinking age can choose not to 
drink, or to drink in moderation by  [CONTACT_783739] 2 drinks or less in a 
day for men and 1 drink or less in a day for women, when alco hol is  
consumed. Drinking less is better for health than drinking more. There are 
some adults who should not drink  alcohol, such as women who are 
pregnant. ” 
10.7.2  Physical Activity  
To safely engage in physical activity, types of physical activity appropriate for  the participant ’s 
current fitness should be chosen. Furthermore, the amount and duration of physical activity 
should be gradually increased over time. Participant s with chronic conditions and symptoms 
should be under the care of a health care provider  who can advise  about the types and amounts of 
physical activity that are appropriate for the participant . 
For this study, c ounseling on physical activity will be based on the Physical Activity Guidelines 
for Americ ans, 2nd Edition  published by [CONTACT_941] U.S. Department of Health and Human Services  
(HHS 2018 ). The following principles form the basis of these guidelines.  
 Key Guidelines for Adults  (age <65 years)  
o “Adults should move more and sit less throughout the day. Some physical activi ty 
is better than none. Adults who sit less and do any amount of moderate -to-
vigorous physical activity gain some health benefits.  
o For substantial health benefits, adults should do at least 150 minutes (2 hours and 
30 minutes) to 300 minutes (5 hours) a we ek of moderate -intensity, or 75 minutes 
(1 hour and 15 minutes) to 150 minutes (2 hours and 30 minutes) a week of 
vigorous -intensity aerobic physical activity, or an equivalent combination of 
moderate - and vigorous -intensity aerobic activity. Preferably, a erobic activity 
should be spread throughout the week.  
o Additional health benefits are gained by [CONTACT_783740] 300 minutes (5 hours) of moderate -intensity physical activity a 
week.  
o Adults should also do muscle -strengt hening activities of moderate or greater 
intensity and that involve all major muscle groups on 2 or more days a week, as 
these activities provide additional health benefits. ” 
 Key Guidelines for Older Adults  (age ≥ 65 years)  
o “The key guidelines for adults also apply to older adults. In addition, the 
following key guidelines are just for older adults:  
▪ As part of their weekly physical activity, older adults should do  
multicomponent physical activity that includes balance training as well as  
aerobic and muscle -strengthening activities.  
▪ Older adults should determine their level of effort for physical activity  
relative to their level of fitness.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 103 ▪ Older adults with chronic conditions should understand whether and how  
their conditions affect their ability to do re gular physical activity safely.  
▪ When older adults cannot do 150 minutes of moderate -intensity aerobic  
activity a week because of chronic conditions, they should be as physically 
active as their abilities and conditions allow. ”  
 Key Guidelines for Adults W ith Chronic Health Conditions and Adults With Disabilities  
o “Adults with chronic conditions or disabilities, who are able, should do at least 
150 minutes (2 hours and 30 minutes) to 300 minutes (5 hours) a week of 
moderate -intensity, or 75 minutes (1 hour a nd 15 minutes) to 150 minutes (2 
hours and 30 minutes) a week of vigorous -intensity aerobic physical activity, or 
an equivalent combination of moderate - and vigorous -intensity aerobic activity. 
Preferably, aerobic activity should be spread throughout the w eek.  
o Adults with chronic conditions or disabilities, who are able, should also do 
muscle -strengthening activities of moderate or greater intensity and that involve 
all major muscle groups on [ADDRESS_1077833] about the types and amounts of activity 
appropriate for their abilities and chronic conditions. ” 
 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 104 10.8. Appendix 8: Protocol GZB F Standardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, and Vital Signs  
The following information has been adapted from standardized physical measurement protocols 
for the World Health O rganization’s STEPwise approach to Surveillance (STEPS) ( WHO 2017 ).  
Measuring Height  
Step 1.  Ask the participant to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_783741]).  
Step 2.  Ask the participant to stand on the calibrated height -measuring board (stadiometer) or 
against a wall with their feet together and their knees straight with their heels against the 
backboard,  the stadiometer , or the wall . 
Step 3.  Ask the participant to look straight ahead without tilting their head up.  
Step 4.  Ask the participant to breathe in and stand tall. Measure and record the participant’s 
height in centimeters  to [ADDRESS_1077834].  
Measuring Weight  
 Body weight measurements should be done in a consistent manner using a calibrated 
electronic sc ale that measures in kg to [ADDRESS_1077835], with a capacity to 
accommodate participants with overweight/obesity . 
 All weights for a given participant should be measured using the same scale, whenever 
possible, at approximately the same time in the morning after evacuation of bladder 
contents .  
 Body weight must be measured in fasting state. If the participant is not fa sting, the 
participant should be called in for a new visit within the visit window to have the 
fasting body weight measured.  
Step 1 . Ask the participant to empty their pockets, remove their footwear, outerwear (coat, 
jacket, etc.), and any headgear (light headgear worn for religious reasons can remain, but this 
should be worn by [CONTACT_291613]).  
Step 2 . Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough,  uneven surface).  
Step [ADDRESS_1077836] Circu mference  
 Waist circumference should be measured in the horizontal plane and at the midpoint 
between the lower margin of the last palpable rib and the top of the iliac crest . 
 Measurements should be taken at the end of a normal expi[INVESTIGATOR_157343] a nonstretcha ble 
measuring tape . The tape should lie flat against the skin without compressing the soft 
tissue.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 105  The waist circumference  should be measured twice, rounded to the nearest 0 .5 cm. 
The measuring tape should be removed between the 2 measurements. Both 
measur ements will be recorded in the eCRF. If the difference between the 2 
measurements exceeds 1  cm, this set of measurements should be discarded and the 2 
measurements repeated.  
Step 1 : Ask the participant to wear little clothing (if available, patient gowns could also be used).  
Step 2 : Ask the participant to stand with their feet close together, arms at their side, body weight 
evenly distributed.  
Step 3 : Ask the participant to relax and measure the participant’s waist circumference.  
Sitting Vital Sign Measure ments  
 Vital sign measurements ( BP and HR, measured by [CONTACT_117682]) should be taken 
before obtaining an ECG tracing and before collection of blood samples for 
laboratory testing.  
 The participant should sit quietly for 5 minutes before vital sign 
measurements are taken.  
 For each parameter, 3 measurements will be taken using the same arm, 
preferably the nondominant arm.  
 The recordings should be taken at least 1 minute apart. Each measurement of 
sitting pulse and BP needs to be recorded in the eCRF.  
 Blood pressure mu st be taken with an automated BP instrument  with full 
range of cuff sizes up to extra -large. 
 If BP and pulse measurements are taken separately, pulse should be taken 
prior to BP.  
Note : In the event pulse measurement cannot be taken via an automated BP instrument, the 
preferred location for measurement of pulse is the radial artery.  
Orthostatic Vital Sign Measurements  
 Orthostatic vital sign measurements ( BP and HR, measured by [CONTACT_117682]) should 
be taken before obtaining an ECG tracing and before collection  of blood 
samples for laboratory testing. They should be done after completing the 
triplicate measures in the sitting position.  
 The participant should lie quietly for 5 minutes before vital sign 
measurements are taken.  
 The participant  should be comfortably  lying flat without legs crossed, in a 
calm, quiet area for 5 minutes before vital sign measurements are taken.  
 For measurement of vital signs in the supi[INVESTIGATOR_2547], t he arm should be 
supported by a pi[INVESTIGATOR_597972] 
(approximately halfway between the bed and the level of the sternum).  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077837] arm positioning results in erroneous BP values.  
o Upper arm below the level of the right atrium (for example, arm 
hanging down) results in readings that are too high.  
o Upper arm abo ve the heart level results in readings that are too low.  
 Measure  BP and pulse rate once in the supi[INVESTIGATOR_2547].  
 After the BP and pulse rate are determined in the supi[INVESTIGATOR_2547], the 
participant  should immediately move to the standing position, bend the ar m 
used for BP determination at the elbow , and rest the arm on an adjustable 
table or stand so that the upper arm is supported at the heart level.  
 Determine the standing BP and pulse rate in the supported arm immediately 
after standing for 3 minutes.  Only 1 measurement is needed . 
 Record all symptoms (AEs) that the participant  may experience , such as 
lightheadedness, syncope, or dizziness as AEs.  
Electrocardiogram  
 12-lead ECGs should be obtained after the participant  has rested in a supi[INVESTIGATOR_783707] 5 minutes.  
 Electrocardiograms should be collected at least 30 minutes prior to collection of 
blood samples for laboratory testing, including PK samples . 
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electronically t ransmitted to a designated central ECG laboratory. The central ECG laboratory 
will perform a basic quality control check (for example, demographics and study details) and 
then store the ECGs in a database. In addition, tracings collected at the baseline, [ADDRESS_1077838] at the central ECG laboratory for further evaluation of 
machine -read measurements or to meet regulatory  requirements at timepoints as per the SoA. 
The machine -read ECG intervals and HR may be used for data analysis and report -writing 
purposes, unless a cardiology overreading of the ECGs is conducted prior to completion of the 
final study report (in which ca se, the overread data would be used) . 
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 108     HBV DNAa Anti-smooth muscle antibody (ASMA)b 
Hepatis C Virus (HCV) Testing:  Anti-actin antibodyc 
    HCV antibody  Epstein -Barr Virus (EBV) Testing:  
    HCV RNAa     EBV antibody  
Hepatitis D Virus (HDV) Testing:      EBV DNAa 
    HDV antibody  Cytomegalovirus (CMV) Testing:  
Hepatitis E Virus (HEV) Testing:      CMV antibody  
    HEV IgG antibody      CMV D NAa 
    HEV  IgM antibody  Herpes Simplex Virus (HSV) Testing:  
    HEV R NAa     HSV (Type 1 and 2) antibody  
Microbiologyd     HSV (Type 1 and 2) DNAa 
Culture:  Liver Kidney Microsomal Type 1 (LKM -1) Antibody  
    Blood   
    Urine   
Abbreviations: EBV = Epstein -Barr Virus ; Ig = immunoglobulin; INR = international normalized ratio.  
a Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
b This is not required if anti -actin antibody is tested.  
c This is not required if anti -smooth musc le antibody is tested.  
d Assayed by [CONTACT_1697] -designated local laboratory ONLY. No central testing available.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 111 10.11.  Appendix  11: Patient-Reported Outcomes  
When feasible, t he self -administered questionnaires will be translated into the native language of 
participants , linguistically validated and administered according to the SoA (Section 1.3). The 
language of the signed ICF will be considered the participant’s native language.  If a translation is 
not available in the native language of a participant  at baseline, the questionnaire(s) will not be 
administered for that participant  for the duration of the trial. If PRO questionnaires are not 
collected due to a translation not being available, this will not be considered a protocol deviation.  
When the PROs are collected as per the SOA , the questionnaires should be completed before the 
participant has discussed their medical condition or progress in the study with the investigator 
and/or site staff, if the participant is not adversely affected by [CONTACT_51993].  
 Patient Global Impression of Status for Physical Activity  
Study participants will be asked to complete a Patient Global Impression of Status 
(PGIs)  for Physical Activ ity item specifically developed for this study. This is a 
participant -rated assessment of current limitation on physical activity due to health and 
is rated on a 5 -point scale ranging from “1 - not at all limited” to “5 - extremely 
limited.”  
 Short Form -36 version 2 Health Survey acute form, 1 -week recall version  
The SF -36v2 acute form, 1 -week recall version  is a 36 -item generic, 
participant -administered measure designed to assess the following 8 domains : 
o Physical Functioning  
o Role -Physical  
o Bodily Pain  
o Gener al Health  
o Vitality  
o Social Functioning  
o Role -Emotional , and   
o Mental Health.  
The Physical Functioning domain assesses limitations due to health “now” while the 
remaining domains assess functioning “in the past week.” Each domain is scored 
individually and information from these 8 domains are further aggregated into 2 health 
component summary scores: Physical Component Summary and Mental Component 
Summary. Items are answered on Likert scales of varying lengths (3 -point, 5 -point, or 6 -
point scales). Scoring o f each domain and both summary scores are norm -based and 
presented in the form of T -scores, with a mean of 50 and SD of 10; higher scores 
indicate better levels of function and/or better health (Maruish 2011).  
 Eating Inventory  
The Eating Inventory is a 51 -item, participant -administered measure designed to assess 
3 aspects of eating behavior (Stunkard and Messick 1985)  
o dietary restraint (21 items)  
o disinhibition (16 items), and  
o perceived hunger (14 items).  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 112 Thirty -six items are rated in true/false format, 14 items are rated on a 4 -point scale, and 
1 item is rated on a 6 -point scale. Dietary restraint refers to both cognitive and 
behavioral dietary restraint, disinhibition measures the tendency to overeat in response 
to external cues, and perceived hunger measu res susceptibility to feelings of hunger. 
Higher domain scores denote higher levels of restrained eating, disinhibited eating, and 
predisposition to hunger, respectively.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 113 10.12.  Appendix  12: Provisions for Changes in Study Conduct during  
Exceptional Circumstanc es 
Implementation of this appendix  
The changes to procedures described  in this appendix are temporary measures intended to be 
used only during specific time periods  as directed by [CONTACT_52019].  
Exceptional circumstances  
Exceptional  circumstances  are rare events  that may cause disruptions to the conduct of the study.  
Examples include  pandemics or natural disasters . These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_427].   
After approval by l ocal Ethical Review Boards, regulatory bodies , and any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required (for example, upon implementation and suspension of changes ). All 
approvals and notifications  must be retained in the study records.  
If the sponsor grants written approval for changes  in study conduct, the sponsor will also p rovide 
additional written guidance , if needed.  
Considerations for making a change  
The prevailing consideration  for making a change is e nsuring the safety of study participants.  
Additional i mportant considerations for making a change are compliance with Good Clinical 
Practice , enabling participants to continue safely in the study  and maintaining the integrity of the 
study.  
Informed consent  
Additional consent from the participant will be obtained , if required,  for: 
 participation in remote visits, as defin ed in Sect ion “Remote Visits”  
 dispensation of additional study drug during an extended treatment period  
 alternate delivery of study drug and ancillary supplies, and 
 provision of their personal or medical information required prior to implementation of 
these activities .  
Changes in study conduct  during exceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed . 
The following changes in study conduct will not be c onsidered protocol deviations.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 114 Remote visits  
Types of remote visits  
Remote visits may apply to Visit s 6, 7, 8, 9, 10, and 14 .  
Any procedures that cannot be accomplished at a remote visit should be conducted at the next  
on-site visit and captured as a protocol deviation related to the exceptional circumstances. Of  
note, procedures from the missed visit that were not collected and are the same as ones at the  
next site visit do not need to be duplicated.  ABPM scheduled for Visit 1 4 (Week 36) should be 
collected as close to the schedule as possible  and before Visit 17 (Week 48) . Electrocardiograms  
may be collected at alternate location s and reviewed  by [CONTACT_783742]; 
however, if collection of centralized ECGs is not feasible  with a  remote visit , they should be 
collected per the S oA at the next in-office visit.  
Telemedicine:  
Telephone or  technology -assisted  virtual visits , or both,  are acceptable to complete 
appropriate assessments . Assessments to be completed in this manner include, but are not 
limited to  
 AEs 
 product complaints  
 concomitant medications  
 diet and physical activity counseling  
 review of study participant diary (including study drug compliance ), and  
 mental health questionnaires ( for example , C-SSRS, PHQ -9). 
Mobile  healthcare:   
Healthcare visits may be performed by a mobile healthcare provider at locations other 
than the study site when participants cannot travel to the site due to an exceptional 
circumstance if written approval is provided by [CONTACT_456] . Procedures performed at 
such visits include, but are not limited to  
 weight and waist measurements  
 brief physical assessments  or general wellness check  
 vital signs  
 collection of blood  and urine  samples , and  
 collection of health information.  
Other alternati ve locations:   
During exceptional circumstances, laboratory samples , and ECGs may be collected  
locally, if needed outside of mobile healthcare visits.   
Data capture  
In source document s and the CRF , the study site should capture the visit method , with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol r equirements regarding the 
reporting of AEs, SAEs, and product complaints remain u nchanged .  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077839] be retained for: PK, immunogenicity, and biomarkers. The local 
laboratory must be qualified in accordance with  applicable  local regulations . 
Study drug  and ancillary supplies (including participant diaries)  
When a  participant  is unable to go to the site to receive study  supplies during normal on -site 
visits, the site should work with the sponsor to determine appropriate actions . These actions may 
includ e  
 asking the  participant to go to the site and receive study  supplies from site staff 
without completion of a full study visit  
 asking the participant ’s designee to go to the site and receive study  supplies on a 
participant’s behalf, and 
 arranging delivery of study supplies . 
These  requirements must be met  before action is taken  
 Alternate delivery of study drug should be performed in a manner that does not 
compromise treatment blinding and ensures product integrity. The existing protocol 
requirements for product accountability remain unchanged , including verification of 
participant’s receipt of study supplies.  
 When delivering supplies to a location other than the study site (for example, 
participant’s home ), the investigator , sponsor , or bot h should ensure oversight of the 
shippi[INVESTIGATOR_597973] ( that is , storage 
conditions maintained  and intact packaging upon receipt) . 
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed  study supplies . 
Screening period guidance   
To ensure safety of study participants, lab oratory  values and other eligibility assessments taken 
at the screening visit  (Visit 1) are valid for a maximum of 70 days prior to the randomization 
visit (Visit 4) . The following rules will be applied for active, nonrandomized participants who se 
participation in the study must be paused due to exceptional circumstances : 
 If screening period is  paused for less than 50 days from screening  (Visit 1)  to Visit 3 
(or Visit 2 for participants identified with increased probability of liver fat ≥10% by 
[CONTACT_783743] ), the participant will proceed to the next study visit per the 
usual SoA, provided that the randomizati on visit (Visit 4) must be conducted within 
[ADDRESS_1077840] screening  (Visit 1) .  
o The site should conduct the next visit if the participant’s eligibility criteria are 
confirmed , and the site should document the reason for delay .  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 116 o Due to the pause in scr eening, sites should also reconfirm the impacted  
participant’s consent and document this confirmation  in the source 
documentation.  
 If screening period is  paused for more than 50 days from screening  (Visit 1) to Visit 3 
(or Visit 2 for participants identified with increased probability of liver fat ≥10% by 
[CONTACT_783743]) , the participant must be discontinued because of screening 
interruption due to an exceptional circumstance. This is docum ented as a screen fail 
in the CRF . This screen fail is allowed in addition to the main protocol screen fail. 
The participant can reconsent and be rescreened as a new participant. The screening 
procedures per the usual SoA should be followed , starting at the screening visit (Visit 
1) to ensure participant eligibility by [CONTACT_329712]  (Visit 4) . 
Adjustments to visit windows   
Whenever possible and safe to do so, as determined by  [CONTACT_093]’s discretion , participants 
should complete the usual SoA. To  maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from th e sponsor . 
This minimizes missing data and preserv es the intended conduct of the stud y. 
 
This table describes the allowed adjustments to visit windows  after randomization (Visit 4) . 
 
Visit Number  Tolerance  
Visit 5  Within 3 days before  the intended date, or up to 3 days after 
the intended date  
Visit 6 
through Visit 
8 Within 7 days before  the intended date, or up to 7 days after 
the intended date  
Visit 9 
through Visit 
17 and Visit 
99 Within 14 days from the intended date, or up to 14 days 
after the intended date  (can be up to 28 days after the 
intended date  for Visit s 11, 17 , and 99 ) 
Visit [ADDRESS_1077841] will be documented:  
 Sites will identify and document the details of how participants, visits types, and 
conducted activities were affected by [CONTACT_52022] . 
Dispensing/shipment records of study drug and re levant communications, including 
delegation, should be filed with site study records.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 117 Source documents at alternate locations  
 Source documents generated at a location other than the study site should be part of 
the investigator’s source documentation and should be transferred to the site in a 
secure and timely manner.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 118 10.13.  Appendix 13: Abbreviations  
Term  Definition  
ABMP  ambulatory  blood pressure monitoring  
AC assessment committee  
ADA s antidrug antibodies  
AE adverse event: any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANCOVA  analysis  of covariance  
AST  aspartate aminotransferase  
BG blood glucose  
blinding/masking  a double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.  
BMI  body mass index  
BP blood pressure  
C-CASA  Columbia Classification Algorithm of Suicide Assessment  
CEC  clinical endpoint committee  
CFR  Code of Federal Regulations  
CHF  congestive heart failure  
CKD -EPI [INVESTIGATOR_783708]  a complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  adherence  to all study -related, good clinical practice, and applicable regulatory 
requirements  
CRF  case report form  
CRP  clinical research physician: individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global safety physician , or other medical officer.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 [ADDRESS_1077842]  
HbA1c  hemoglobin A1c  
HDL  high-density lipoprotein  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 120 hERG  
HR Human ether -a-go-go-related gene  
heart rate  
IB Investigator’s Brochure  
ICF informed consent form  
ICH  International Council for  Harmonization  
IEC Independent Ethics Committees  
Informed consent  a process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by [CONTACT_3553] a written, signed and dated informed consent form . 
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
investigational 
product  a pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the au thorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IWRS  interactive web -response system  
LDL  low-density lipoprotein  
MAD  multiple ascending dose  
MedDR A Medical Dictionary for Regulatory Activities  
MEN  multiple endocrine neoplasia  
MMRM  mixed -model for repeated measures  
MRI  magnetic resonance imaging  
MRI -PDFF  magnetic resonance imaging -derived proton density fat fraction  
MTC  medullary thyroid carcinoma  
NAFLD  non-alcoholic fatty liver disease  
NYHA  [LOCATION_001] Heart Association  
participant  equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control . 
PC product complaint  
PHQ -9 Patient Health Questionnaire -9 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 121 PK/PD  pharmacokinetics/pharmacodynamics  
PR pulse rate  
PRO/ePRO  patient -reported outcomes/electronic patient -reported outcomes  
QW once weekly  
RNA  ribonucleic acid  
SAE  serious adverse  event  
SAP  statistical analysis plan  
SC subcutaneous  
screen  the act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
SF-36 v2  Short -Form -36 Health Survey  (SF-36), version 2  
SMBG  self-monitored blood glucose  
S[LOCATION_003]Rs  suspected unexpected serious adverse reactions  
T1D  Type 1 diabetes  
T2D  Type 2 diabetes  
TBL  total bilirubin level  
TE treatment emergent  
TEAE  treatment -emergent adverse event: an untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship with this 
treatment.  
ULN  upper limit of normal  
WOCBP  women of childbearing potential  
WNOCBP  women not of childbearing potential  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 122 10.14.  Appendix 14: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment a: 21-May -2021  
Overall Rationale for the Amendment:  
The overall changes and rationale for the changes made to this protocol are described in the 
following table. Note that minor edits have been made throughout the protocol, which are not 
captured in the table  below . 
Section # and Name  [CONTACT_9353] 1.3 Schedule of 
Activities  Added  the following note to 
Patient -Reported Outcomes 
(PROs) , “If a PRO questionnaire 
is not available in the native 
language of a participant at 
baseline, that questionnaire will 
not be administered for that 
participant for the duration of 
the trial (Appendix 10.10)”  If a PRO questionnaire is not 
available in the native language, 
then there is no scientific value 
in collecting these data as 
participants would not be able to 
meaningfully understand and 
provide appropriate responses to 
the questions  
Removed Predose 
Pharmacokinetic (PK) sample  
collection at Visit 801  Correction in timepoint for  PK 
sample collection at Visit 801  
Updated the general notes to 
include information on 
ambulatory blood pressure  
modeling  (ABPM)  If the ABPM needs to be 
repeated at Visit 3, then the 
screening period may exceed 6 
weeks and this will not be 
considered a protocol deviation  
Section 4.1.1  
Overview of Study 
Periods  Addition of “when collected” for 
PROs at Visit 4, during 
maintenance period ( Visit 11 
and Visit 17 ), and during e arly 
discontinuation of treatment visit To be aligned with PROs in 
Schedule of Events  
Section 5.2 Exclusion 
Criteria  Addition of history of 
symptomatic gallbladder disease  To address Food and Drug 
Administration  (FDA ) feedback  
Addition of history of 
documented human 
immunodeficiency virus  
infection  Medications used to treat HIV 
infection may affect body fat 
distribution  
Revised language for 
implantable or injectable 
contraceptives  Clarified  that intrauterine 
devices are allowed if the 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 123 Section # and Name  [CONTACT_783744] [ADDRESS_1077843] previously 
received LY3437943  Minor edit to clarify language  
Inclusion and E xclusion Criteria  
1–51 and 58 –59 can be referred 
to in the current protocol  
 
For inclusion and E xclusion 
Criteria  52–57, refer to J1I-MC-
GZBF  Addendum (1)  The inclusion and exclusion 
criteria numbered from 52 to 57 
are part of J1I-MC-GZBF  
Addendum (1). So, in the current 
protoc ol, the exclusion criteria 
continue with the next available 
number  in the sequence from the 
last number in the protocol 
addendum  (58–59) 
Section 8.3.1 Timing 
and Mechanism for 
Collecting Events  Change of “Pregnancy eCRF ” to 
“SAE eCRF ” Correction in mechan ism for 
reporting  
Section 10.2 Appendix 
2: Clinical Laboratory 
Tests  Removed uric acid from clinical 
chemistry  tests To maintain internal document 
consistency. It is presented in 
Appendix 1 0 as biomarker of 
purine metabolism  
Added LTS P800 to exploratory 
samples  Addition of plasma metabolic 
marker  
Section 10.8 Appendix 
8: Protocol GZBF 
Standardized Protocols 
for the Measurement of 
Height, Weight, Waist 
Circumference, and 
Vital Signs  Updated electrocardiogram 
tracings to be assessed 
qualitatively by a blinded 
cardiologist  To maintain consistency  with 
Section 8.2.3 
(Electrocardiograms)  
Section 10.11 Appendix 
11: Patient -Reported 
Outcomes  Added information to clarify that 
PRO questionnaires will be 
translated into the native 
language o f participants if 
feasible. If a translation is not 
available in the native language 
of a participant, then that PRO 
questionnaire will not be 
administered for that participant 
for the duration of the trial  If a PRO questionnaire is not 
available in the na tive language, 
then there is no scientific value 
in collecting the data as 
participants would not be able to 
meaningfully understand and 
provide appropriate responses to 
the questions   
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 124 11. References  
[ADA] American Diabetes Association. 6. Glycemic targets: standards of medical care in 
diabetes -2020. Diabetes Care . 2020 ;43(suppl 1):S66 -S76. https://doi.org/10.2337/dc20 -S006  
[AMA] American Medical Association. American Medical Association House of Delegates 
resolution: 420 (A -13): recognition  of obesity as a disease. May 2013. Accessed May 21, 2020. 
https://media.npr.org/documents/2013/jun/ama -resolution -obesity.pdf  
Aroda VR, Ratner R. The safety and tolerability of GLP -1 receptor agonists in the treatment of 
type 2 diabetes: a review. Diabete s Metab Res Rev . 2011;27(6):528 -542. 
https:// doi.org/10.1002/dmrr.1202  
Banks PA, Freeman ML; Practice Parameters Committee of the American College of 
Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol.  
2006;101(10):2379 -2400. https://doi.org/10.1111/j.[ADDRESS_1077844]: a scalable tree boosting system. In proceedings of the 22nd ACM 
SIGKDD international conference on knowledge discovery and data mining (KDD ʼ16). 
Association for computing machin ery, [LOCATION_001], NY, [LOCATION_003] . 2016 ;785-794. 
https://doi.org/10.1145/2939672.2939785  
Council on Science and Public Health. Report of the Council on Science and Public Health: is 
obesity a disease? (Resolution 115 -A-12). Report number: 3 -A-13. 2013. Accessed May 2 1, 
2020. https://www.ama -assn.org/sites/ama -assn.org/files/corp/media -browser/public/about -
ama/councils/Council%20Reports/council -on-science -public -health/a13csaph3.pdf  
Danne T, Philotheou A, Goldman D, et al. A randomized trial comparing the rate of 
hypog lycemia – assessed using continuous glucose monitoring – in 125 preschool children with 
type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL stud y). Pediatr 
Diabetes . 2013;14(8):593 -601. https:// doi/10.1111/pedi.[ZIP_CODE]  
[FDA] Food and  Drug Administration. Guidance for Industry. Developi[INVESTIGATOR_261721]. 2007. Accessed January 27, 2021. https://www.fda.gov/media/[ZIP_CODE]/download  
[HHS]  U.S. Department of Health and Human Services. Physical Activity  Guidelines for 
Americans , 2nd edition . Washington, DC: U.S. Department of Health and Human Services;  
2018 . Accessed February 22, 2021.  https:// Physical Activity Guidelines for Americans 2nd 
edition (health.gov)   
Koizumi M, Takada T, Kawarada Y, et al. JPN guidelines for the management of acute 
pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 -32. https://doi.org/10.1007/s00534 -005-1048 -2 
Kroenke K, Spi[INVESTIGATOR_4280], Williams JB. The PHQ -9: validity of a bri ef depression severity 
measure.  J Gen Intern Med.  2001;16(9):606 –613. https:// doi.org/10.1046/j.1525 -
1497.2001.016009606.x  
Lauby -Secretan B, Scoccianti C, Loomis D, et al .; International Agency for Research on Cancer 
Handbook Working Group. Body fatness an d cancer -viewpoint of the IARC Working Group. N 
Engl J Med.  2016;375(8):794 -798. https://doi.org/10.1056/NEJMsr1606602  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBF  (b) 
 125 Luppi[INVESTIGATOR_4276], de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic 
review and meta -analysis of longitudinal studies. Arch Gen Psychiatry.  2010;67(3):220 -229. 
https://doi.org/10.1001/archgenpsychiatry.2010.2  
Maruish ME, ed itor. User’s Manual for the SF -36v2 Health Survey . 3rd ed. Quality Metric 
Incorporated; 2011.  
Moriarty AS, Gilbody S, McMillan D, Manea L. Screening and case finding for major depressive 
disorder using the Patient Health Questionnaire. Gen Hosp Psychiatry.  2015;37(6):567 -576. 
https://doi.org/ 10.1016/j.genhosppsych.2015.06.012  
Nauck MA, Meier JJ, Schmidt WE. Incretin -based  glucose -lowering medications and the risk of 
acute pancreatitis and/or pancreatic cancer: reassuring data from cardio -vascular outcome trials. 
Diabetes Obes Metab . 2017;19(9):1327 -1328. https://doi.org/10.1111/dom.[ZIP_CODE]  
O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared 
with liraglutide and placebo for weight loss in patients with obesity: a randomised, double -blind, 
placebo and active controlled, dose -ranging, phase 2 trial. Lancet . 2018;392([ZIP_CODE]):637 -649. 
https://do i.org/ 10.1016/S0140 -6736(18)[ADDRESS_1077845] AJ, Messick S . The three -factor eating questionnaire to measure  dietary restraint, 
disinhibition and hung er. J Psychosom Res . 1985;29(1):71 -83. https://doi .org/1 0.1016/0022 -
3999(85)[ZIP_CODE] -8 
Steinberg WM, Buse JB,  Ghorbani MLM, et al .; LEADER Steering Committee; LEADER Trial 
Investigators. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with 
liraglutide: results from the LEADER randomized trial. Diabetes Care.  2017a;40(7):966 -972. 
https://doi.org/10.2337/dc16 -[ADDRESS_1077846] of liraglutide on amylase, lipase, and 
acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or 
type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development 
program. Diabetes Care.  2017b;40(7):839 -848. https://doi.org/10.2337/dc16 -2684  
[USDA and HHS] U.S. Department of Agriculture and U.S. Department of Health and Human 
Services. Dietary Guidelines for Americans, 2020 -2025. 9th Edition . 2020. Accessed February 
22, 2021. https:// Dietary Guidelines for Americans , 2020 -2025  
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequently repeated glucose measurements 
overestimate the incidence of i npatient hypoglycemia and severe hyperglycemia.  J Diabetes Sci 
Techno l. 2010;4(3):577 -582. https:// doi.org/ 10.1177/193229681000400311  
[WHO] World Health Organization. WHO STEPS surveillance manual: the WHO STEPwise 
approach to noncommunicable disease risk factor surveillance.  Updated January 26, 2017. 
Accessed May 04, 2020. https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf  
Approved on 29 Aug 2022 GMT